- Condition: Psoriasis
Interventions: Drug: 80 mg ixekizumab Dosing Regimen; Drug: 50 mg etanercept; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012 - Condition: Skin Infection
Intervention: Drug: CG400549
Sponsors: CrystalGenomics, Inc.; CrystalGenomics, Inc.
Not yet recruiting - verified May 2012 - Condition: Breast Cancer
Intervention:
Sponsors: Genentech; Genentech; 23andMe, Inc.
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention: Drug: enzalutamide
Sponsors: Medivation, Inc.; Medivation, Inc.; Astellas Pharma Inc
Recruiting - verified May 2012 - Condition: Advanced HER2-positive Breast Cancer
Interventions: Drug: LJM716; Drug: Trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: PLX3397; Drug: Eribulin
Sponsors: University of California, San Francisco; Hope Rugo, MD; Susan G. Komen Breast Cancer Foundation; Plexxikon, Inc.; Eisai Inc.
Not yet recruiting - verified May 2012 - Conditions: Lung Cancer; Non Small Cell Lung Cancer (NSCLC); Breast Cancer; ER+ Breast Cancer
Interventions: Drug: entinostat; Drug: entinostat; Drug: Erlotinib; Drug: Erlotinib; Drug: Exemestane; Drug: Exemestane
Sponsors: Syndax Pharmaceuticals; Syndax Pharmaceuticals
Recruiting - verified May 2012 - Conditions: HER2 + Breast Cancer; HER2 + Gastric Cancer; Squamous Cell Carcinoma of Head and Neck
Intervention: Drug: LJM716
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Prospective Chart-Review: Impact of Combination - Digital Breast Tomosynthesis + Digital MammographyCondition: Breast Cancer
Intervention:
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified May 2012 - Conditions: Hand Eczema; Foot Eczema
Interventions: Drug: Retapamulin 1% ointment; Drug: Placebo
Sponsors: Mount Sinai School of Medicine; Gary Goldenberg
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Eribulin; Drug: 5-Fluorouracil; Drug: Epirubicin; Drug: Cyclophosphamide; Drug: Doxorubicin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Eisai Inc.
Not yet recruiting - verified May 2012 - Conditions: Surgical Wound; Hypo-pigmented Skin
Intervention: Device: Momelan Technologies Epidermal Graft Harvesting System
Sponsors: Momelan Technologies; Momelan Technologies
Recruiting - verified May 2012 - Condition: Facial Acne
Intervention: Device: Ulthera System Treatment
Sponsors: Ulthera, Inc; Ulthera, Inc
Recruiting - verified May 2012 - Condition: Alopecia
Intervention: Biological: PRFM treatment
Sponsors: The New York Eye & Ear Infirmary; The New York Eye & Ear Infirmary
Recruiting - verified May 2012 - Conditions: Hyperhydrosis; Depression
Intervention: Drug: Glycopyrrolate
Sponsors: Thomas Jefferson University; Thomas Jefferson University
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention: Other: Radiation Therapy
Sponsors: New York University School of Medicine; New York University School of Medicine
Recruiting - verified May 2012 - Conditions: Cancer Survivor; Breast Cancer; Colorectal Cancer; Gynecological Cancer; Ovarian Cancer; Uterine Cancer
Intervention: Behavioral: Mindfulness Based Cancer Recovery
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Not yet recruiting - verified May 2012 - Condition: Tinea Pedis
Interventions: Drug: Butenafine HCl Cream, 1%; Drug: Lotrimin Ultra®; Drug: Butenafine Vehicle
Sponsors: Taro Pharmaceuticals USA; Taro Pharmaceuticals USA
Recruiting - verified April 2012 - Condition: Tinea Pedis
Interventions: Drug: Naftifine HCl Cream 1%; Drug: Naftin® (Naftifine HCl) Cream 1%; Drug: Placebo topical cream
Sponsors: Taro Pharmaceuticals USA; Taro Pharmaceuticals USA
Not yet recruiting - verified April 2012 - Conditions: Alopecia; Breast Cancer
Intervention: Drug: compound 31543 Calcitriol
Sponsors: Berg Pharma,LLC; Berg Pharma,LLC
Not yet recruiting - verified April 2012 - Condition: Breast Neoplasms
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Squamous Cell Carcinoma of the Skin; Stage I Squamous Cell Carcinoma of the Hypopharynx; Stage I Squamous Cell Carcinoma of the Larynx; Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage I Squamous Cell Carcinoma of the Oropharynx; Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage I Verrucous Carcinoma of the Larynx; Stage I Verrucous Carcinoma of the Oral Cavity; Stage II Squamous Cell Carcinoma of the Hypopharynx; Stage II Squamous Cell Carcinoma of the Larynx; Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage II Squamous Cell Carcinoma of the Oropharynx; Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage II Verrucous Carcinoma of the Oral Cavity
Interventions: Drug: erlotinib hydrochloride; Procedure: therapeutic conventional surgery
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention: Other: Reflexology
Sponsors: Michigan State University; Michigan State University; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Foot Ulcer, Diabetic
Intervention:
Sponsors: Temple University; Temple University
Recruiting - verified June 2011 - Condition: Pancreatic Ductal Adenocarcinoma
Intervention: Drug: Doxorubicin-EMCH
Sponsors: CytRx; CytRx
Not yet recruiting - verified May 2012 - Condition: Psoriasis
Interventions: Drug: BI 655066 (high medium i.v. dose); Drug: BI 655066 (very low i.v. dose); Drug: BI 655066 (low i.v. dose); Drug: BI 655066 (low medium i.v. dose); Drug: BI 655066 (low s.c. dose); Drug: BI 655066 (high i.v. dose); Drug: BI 655066 (very high i.v. dose); Drug: Placebo, i.v.; Drug: BI 655066 (high s.c. dose); Drug: Placebo, s.c.
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Breast Cancer; Pain, Postoperative; BRCA1 Mutation; BRCA2 Mutation; Breast Diseases; Neoplasms
Interventions: Drug: Botulinum Toxin Type A; Drug: Sodium Chloride Solution
Sponsors: Mayo Clinic; Mayo Clinic
Not yet recruiting - verified May 2012 - Conditions: Chemical Injuries; Unspecified Complication of Corneal Transplant; Autoimmune Diseases; Ocular Cicatricial Pemphigoid; Stevens Johnson Syndrome; Lupus Erythematosus, Systemic; Rheumatoid Arthritis; Other Autoimmune Diseases
Intervention: Drug: Riboflavin
Sponsors: Massachusetts Eye and Ear Infirmary; Massachusetts Eye and Ear Infirmary
Recruiting - verified April 2012 - Condition: Hereditary Angioedema Types I and II
Interventions: Biological: C1-esterase inhibitor - single intravenous dose; Biological: C1-esterase inhibitor - subcutaneous low dose; Biological: C1-esterase inhibitor - subcutaneous medium dose; Biological: C1-esterase inhibitor - subcutaneous high dose
Sponsors: CSL Behring; CSL Behring; Parexel
Recruiting - verified May 2012 - Conditions: Breast Cancer; Lymphedema
Intervention:
Sponsors: Stanford University; Stanley Rockson
Recruiting - verified April 2012 - Conditions: Dose Escalation; Safety; Preliminary Efficacy; Advanced Solid Tumors; Metastatic Breast Cancer; Advanced Pancreatic Adenocarcinoma; Metastatic Colorectal Cancer; Recurrent Glioblastoma Multiforme
Intervention: Drug: LDE225 and BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: tivantinib; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: mutation analysis; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Dana-Farber Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Herpes Labialis
Intervention: Drug: acyclovir/hydrocortisone cream
Sponsors: Meda Pharmaceuticals; Meda Pharmaceuticals; TKL Research, Inc.
Recruiting - verified April 2012 - Condition: Porphyria Cutanea Tarda
Interventions: Drug: Hydroxychloroquine; Procedure: Phlebotomy
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston
Recruiting - verified April 2012 - Condition: Dermatomyositis Associated Superficial Calcinosis
Interventions: Device: Fractional Carbon Dioxide (FCO2) Laser (Candela QuadraLase (TM)); Drug: Sodium thiosulfate
Sponsors: George Washington University; George Washington University
Not yet recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: BKM120; Drug: Paclitaxel; Drug: BKM120 matching placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Cancer
Interventions: Behavioral: survey, questionaire; Behavioral: survey, questionaire
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; St. Jude Children's Research Hospital; University of Colorado Cancer Center, Denver, CO; Dana-Farber Cancer Institute; University of Chicago
Recruiting - verified April 2012 - Condition: Mild to Moderate Atopic Dermatitis
Intervention: Drug: HL-009 Liposomal Gel
Sponsors: HanAll BioPharma Co., Ltd.; HanAll BioPharma Co., Ltd.
Recruiting - verified March 2012 - Conditions: Breast Cancer; Obesity
Intervention: Behavioral: Exercise
Sponsors: University of Mississippi Medical Center; University of Mississippi Medical Center
Recruiting - verified April 2012 - Condition: Psoriasis
Interventions: Drug: STF 115469 Foam; Drug: Vehicle Foam
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified May 2012 - Condition: Breast Cancer
Intervention: Other: MRI
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified March 2012 - Condition: Breast Cancer
Intervention:
Sponsors: Rose Imaging Specialists, P.A.; Rose Imaging Specialists, P.A.; Hologic, Inc.
Recruiting - verified March 2012 - Conditions: Cutaneous Lymphoma; Other Skin Disorders; Mycosis Fungoides
Intervention:
Sponsors: Stanford University; Stanford University
Not yet recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab [Herceptin]; Drug: pertuzumab; Drug: trastuzumab [Herceptin]; Drug: vinorelbine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: X-linked Hypohidrotic Ectodermal Dysplasia
Intervention: Drug: EDI200
Sponsors: Edimer Pharmaceuticals; Edimer Pharmaceuticals
Not yet recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: Herceptin; Drug: NeuVax vaccine; Drug: GM-CSF
Sponsors: San Antonio Military Medical Center; COL George Peoples, MD, FACS; Genentech; Galena Biopharma, Inc.
Not yet recruiting - verified April 2012 - Condition: Advanced Solid Tumors, Excluding Breast Cancer
Interventions: Drug: caffeine; Drug: diclofenac; Drug: omeprazole; Drug: midazolam; Drug: TKI258
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Venous Stasis Ulcers
Intervention: Device: Novel Dressing
Sponsors: Hollister Incorporated; Hollister Incorporated
Recruiting - verified March 2012 - Condition: Breast Cancer
Intervention: Drug: Ruxolitinib
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Not yet recruiting - verified March 2012 - Conditions: Scleroderma, Systemic; Sclerosis, Systemic; Systemic Scleroderma; Systemic Sclerosis
Interventions: Drug: Pomalidomide (CC-4047); Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Not yet recruiting - verified April 2012 - Condition: Psoriasis
Interventions: Drug: Ustekinumab 45 mg; Drug: Ustekinumab 90 mg; Drug: Placebo
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2012 - Conditions: Basal Cell Nevus Syndrome; Gorlin's Syndrome
Interventions: Drug: GDC-0449; Procedure: Aminolevulinic acid %20 topical solution + blue light
Sponsors: Children's Hospital & Research Center Oakland; Children's Hospital & Research Center Oakland; Genentech
Not yet recruiting - verified March 2012 - Condition: Psoriasis
Intervention: Drug: calcipotriene
Sponsors: GlaxoSmithKline; Stiefel, a GSK Company; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Acne Scarring of the Face
Interventions: Drug: Normal Saline; Device: Artefill
Sponsors: Suneva Medical, Inc.; Suneva Medical, Inc.
Recruiting - verified March 2012 - Condition: Moderate to Severe Plaque Psoriasis
Intervention: Other: No intervention
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Plasma Cell Neoplasm; Poor Prognosis Metastatic Gestational Trophoblastic Tumor; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Neuroblastoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage II Ovarian Epithelial Cancer; Stage II Ovarian Germ Cell Tumor; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Small Lymphocytic Lymphoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Breast Cancer; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Small Lymphocytic Lymphoma
Interventions: Procedure: management of therapy complications; Procedure: musculoskeletal complications management/prevention
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Not yet recruiting - verified May 2012 - A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp PsoriasisConditions: Scalp Psoriasis; Plaque Psoriasis
Interventions: Drug: Ustekinumab; Drug: Placebo
Sponsors: Yamauchi, Paul Steven, M.D., Ph.D.; Paul Steven Yamauchi, MD, PhD; Janssen Services, LLC
Not yet recruiting - verified March 2012 - Condition: Breast Neoplasms
Interventions: Drug: lapatinib ditosylate; Biological: trastuzumab
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Not yet recruiting - verified March 2012 - Condition: Diabetic Foot Ulcers
Interventions: Other: Tissue; Other: Control
Sponsors: Osiris Therapeutics; Osiris Therapeutics
Recruiting - verified May 2012 - Conditions: Breast Cancer; Breast Reconstruction; Mastectomy
Intervention: Device: Laser-Assisted ICG Dye Angiography (SPY System)
Sponsors: Stony Brook University; Stony Brook University
Recruiting - verified March 2012 - Conditions: Malignant Solid Tumour; Breast Cancer Nos Metastatic Recurrent; Neuropathy
Intervention: Drug: Eribulin in Combination w/ Cyclophosphamide
Sponsors: University of California, San Francisco; University of California, San Francisco; Eisai Inc.
Not yet recruiting - verified March 2012 - Condition: Venous Leg Ulcers
Intervention: Device: MIST Therapy
Sponsors: Celleration, Inc.; Celleration, Inc.
Not yet recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: AC regimen; Drug: TAC regimen; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Diabetic Complications
Interventions: Device: Prontosan; Device: Saline
Sponsors: B. Braun Medical Inc.; B. Braun Medical Inc.
Recruiting - verified May 2012 - Condition: Venous Leg Ulcer
Interventions: Other: 1 application of EpiFix; Other: 2 applications of EpiFix; Other: Standard of care
Sponsors: MiMedx Group, Inc.; MiMedx Group, Inc.
Recruiting - verified March 2012 - Conditions: Breast Cancer; Colon Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Diabetic Foot Ulcer
Interventions: Other: Standard of care; Other: Applications of EpiFix
Sponsors: MiMedx Group, Inc.; MiMedx Group, Inc.
Recruiting - verified March 2012 - Condition: Allergic Contact Dermatitis
Intervention: Other: Patch tests
Sponsors: Rockefeller University; Rockefeller University
Recruiting - verified March 2012 - Conditions: Scleroderma; Systemic Sclerosis; Diffuse Scleroderma; Diffuse Systemic Sclerosis
Interventions: Drug: Rilonacept; Drug: Placebo
Sponsors: Boston University; Boston University; Regeneron Pharmaceuticals
Recruiting - verified February 2012 - Conditions: Malignant Neoplasm of Breast; Breast Radiotherapy; Breast Diseases; Ductal Breast Carcinoma; Intraoperative Radiotherapy
Intervention: Radiation: Intraoperative radiation therapy (IORT)
Sponsors: University of California, San Francisco; University of California, San Francisco; H. Lee Moffitt Cancer Center and Research Institute; Northwestern University; Los Angeles Women's Health Clinic of California Hospital and Medical Center
Not yet recruiting - verified April 2012 - Condition: Breast Cancer
Intervention: Drug: ARQ 197
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Not yet recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Device: 3Dimensional Mammography; Device: 2D FFDM
Sponsors: Fujifilm Medical Systems USA, Inc.; Fujifilm Medical Systems USA, Inc.
Recruiting - verified March 2012 - Condition: Early Stage Breast Cancer
Intervention: Drug: Denosumab
Sponsors: University of California, San Francisco; Hope Rugo, MD; University of California, San Francisco; Amgen
Not yet recruiting - verified March 2012 - Condition: Stage, Breast Cancer
Interventions: Behavioral: Brief behavioral treatment for insomnia and bright light; Behavioral: treatment as usual
Sponsors: University of California, San Diego; University of California, San Diego
Not yet recruiting - verified February 2012 - Condition: Dystrophic Epidermolysis Bullosa
Intervention: Drug: Granulocyte Colony Stimulating Factor (GCSF)
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: Fulvestrant; Drug: Ganetespib
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Not yet recruiting - verified March 2012 - Condition: Psoriasis, Plaque-type Psoriasis
Interventions: Drug: secukinumab; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Hereditary Coproporphyria (HCP); Acute Intermittent Porphyria (AIP); Variegate Porphyria (VP)
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco; University of Texas; University of Alabama at Birmingham; Mount Sinai School of Medicine; University of Utah; Carolinas Medical Center; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Rare Diseases Clinical Research Network
Recruiting - verified March 2012 - Impact of Body Weight on Pharmacokinetic Analysis of Doxorubicin + Cyclophosphamide in Breast CancerCondition: Breast Cancer
Intervention:
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; Texas Tech University Health Sciences Center
Not yet recruiting - verified January 2012 - Condition: Cutaneous Abscess
Interventions: Drug: Chlorhexidine gluconate; Drug: Mupirocin
Sponsors: Tufts Medical Center; Tufts Medical Center
Recruiting - verified March 2012 - Condition: Actinic Keratosis
Interventions: Procedure: Cryotherapy; Drug: Vehicle; Drug: Ingenol metabute
Sponsors: LEO Pharma; LEO Pharma
Recruiting - verified March 2012 - Conditions: Acute Porphyrias; Cutaneous Porphyrias
Intervention:
Sponsors: Mount Sinai School of Medicine; Mount Sinai School of Medicine
Recruiting - verified March 2012 - Conditions: Psoriasis; Cardiovascular Disease
Interventions: Drug: Adalimumab (Humira); Drug: Placebo Injection; Other: NB-UVB phototherapy
Sponsors: University of Pennsylvania; University of Pennsylvania
Not yet recruiting - verified March 2012 - Condition: Ostomy
Intervention:
Sponsors: ConvaTec Inc.; ConvaTec Inc.
Recruiting - verified February 2012 - Condition: Younger Breast Cancer Survivors
Intervention: Behavioral: Mindful Awareness practices (MAPs)
Sponsors: Jonsson Comprehensive Cancer Center; Jonsson Comprehensive Cancer Center; Susan G. Komen Breast Cancer Foundation
Recruiting - verified March 2012 - Condition: Neoplasm of Skin
Intervention: Device: Momelan Technologies Epidermal Graft Harvesting System
Sponsors: Momelan Technologies; Momelan Technologies
Recruiting - verified February 2012 - Conditions: Breast Cancer; Obesity
Interventions: Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: Texas Tech University Health Sciences Center; Texas Tech University Health Sciences Center; University of Texas
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention: Behavioral: Improving Cognition with group intervention
Sponsors: Jonsson Comprehensive Cancer Center; Jonsson Comprehensive Cancer Center; Breast Cancer Research Foundation
Recruiting - verified April 2012 - Condition: Radiodermatitis
Intervention: Drug: Norepinephrine
Sponsors: ProCertus BioPharm, Inc; ProCertus BioPharm, Inc; H. Lee Moffitt Cancer Center and Research Institute
Recruiting - verified March 2012 - Combination Therapy With 5-FU and PDT for the Treatment of Post-transplant Premalignant Skin DiseaseConditions: Actinic Keratosis; Solid Organ Transplant With Actinic Keratosis
Intervention: Drug: 5-Fluorouracil
Sponsors: The Cleveland Clinic; The Cleveland Clinic; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Cellulitis; Skin Infections
Interventions: Drug: Daptomycin; Drug: Vancomycin
Sponsors: University of Cincinnati; University of Cincinnati
Not yet recruiting - verified March 2012 - Conditions: Sturge Weber Syndrome; Port Wine Mark
Interventions: Drug: Timolol; Drug: Balanced salt ophthalmic solution
Sponsors: Wills Eye; Wills Eye; University of Medicine and Dentistry New Jersey
Not yet recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Other: Tracking & Feedback; Other: Control
Sponsors: Mount Sinai School of Medicine; Mount Sinai School of Medicine; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Other: Bioimpedance Spectroscopy
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified February 2012 - Condition: Sclerosis, Systemic
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: Placebo; Drug: tocilizumab [RoActemra/Actemra]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Breast Cancer; Tobacco Dependence
Interventions: Drug: placebo; Drug: varenicline
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Pfizer
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Biological: 9 Peptides from Her-2/neu, CEA, & CTA + poly-ICLC
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified February 2012 - Condition: Skin Cancer
Intervention:
Sponsors: Northwestern University; Northwestern University
Recruiting - verified February 2012 - Condition: Rosacea
Intervention: Procedure: Pulse Dye Laser/YAG laser
Sponsors: Northwestern University; Northwestern University
Recruiting - verified February 2012 - Conditions: Hot Flashes; Breast Cancer
Interventions: Drug: solifenacin; Drug: Clonidine
Sponsors: University of Arkansas; University of Arkansas
Recruiting - verified February 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Aplastic Anemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Congenital Amegakaryocytic Thrombocytopenia; Diamond-Blackfan Anemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Paroxysmal Nocturnal Hemoglobinuria; Peripheral T-cell Lymphoma; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis; Severe Combined Immunodeficiency; Severe Congenital Neutropenia; Shwachman-Diamond Syndrome; Splenic Marginal Zone Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Waldenstrom Macroglobulinemia; Wiskott-Aldrich Syndrome
Interventions: Drug: fludarabine phosphate; Drug: melphalan; Radiation: total-body irradiation; Drug: tacrolimus; Drug: mycophenolate mofetil; Drug: methotrexate; Other: laboratory biomarker analysis; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012 - Condition: Pseudoxanthoma Elasticum
Interventions: Drug: Magnesium Oxide; Drug: Placebo
Sponsors: Mount Sinai School of Medicine; Mark Lebwohl
Not yet recruiting - verified February 2012 - Conditions: Allergic Asthma; Allergic Dermatitis; Allegic Rhinitis
Interventions: Drug: Omalizumab; Drug: Placebo; Drug: MEDI4212
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2012 - Conditions: Major Cutaneous Abscess; Cellulitis; Erysipelas
Intervention: Drug: TR701 FA
Sponsors: Trius Therapeutics, Inc.; Trius Therapeutics, Inc.; Bayer
Recruiting - verified January 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: Dovitinib; Drug: Fulvestrant
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Locally Advanced HER2-Negative Breast Cancer
Interventions: Drug: Eribulin Mesylate; Drug: Cyclophosphamide; Drug: Docetaxel
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Eisai Inc.
Not yet recruiting - verified March 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; High Risk Metastatic Gestational Trophoblastic Tumor; Juvenile Myelomonocytic Leukemia; Low Risk Metastatic Gestational Trophoblastic Tumor; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Plasma Cell Neoplasm; Previously Treated Childhood Rhabdomyosarcoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Gestational Trophoblastic Tumor; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Neuroblastoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Small Lymphocytic Lymphoma; Recurrent Wilms Tumor and Other Childhood Kidney Tumors; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage II Ovarian Epithelial Cancer; Stage II Ovarian Germ Cell Tumor; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Small Lymphocytic Lymphoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Breast Cancer; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: atorvastatin calcium; Procedure: peripheral blood stem cell transplantation; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Drug: PM01183
Sponsors: PharmaMar; PharmaMar
Not yet recruiting - verified January 2012 - Conditions: Melanoma; Merkel Cell Carcinoma; Squamous Cell Carcinoma; Penile Carcinoma; Urethral Carcinoma; Extramammary Paget's Disease; Scrotal Carcinoma; Anal Cancer; Vulvar Cancer; Skin Cancer; Lymphadenopathy
Interventions: Procedure: Videoscopic procedure; Procedure: Open, traditional approach
Sponsors: Emory University; Emory University
Recruiting - verified February 2012 - Condition: Cutaneous Abscess
Intervention: Device: Xpert MRSA/SA SSTI
Sponsors: George Washington University; George Washington University; Johns Hopkins University
Recruiting - verified January 2012 - Conditions: Inflammatory Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel albumin-stabilized nanoparticle formulation; Other: laboratory biomarker analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Chronic Venous Hypertension With Ulcer
Intervention: Device: ActiVAC System + Compression therapy
Sponsors: Georgetown University; Georgetown University
Not yet recruiting - verified April 2012 - Condition: Acne Vulgaris
Interventions: Drug: Epiduo Gel; Drug: Retin-A Micro Microsphere 0.1%
Sponsors: Galderma Laboratories, L.P.; Galderma Laboratories, L.P.
Recruiting - verified March 2012 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid TumorsConditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Primary Hepatocellular Carcinoma; Chondrosarcoma; Clear Cell Sarcoma of the Kidney; Conjunctival Kaposi Sarcoma; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Hormone-resistant Prostate Cancer; Limited Stage Small Cell Lung Cancer; Localized Resectable Adult Primary Liver Cancer; Male Breast Cancer; Mast Cell Sarcoma; Ovarian Sarcoma; Recurrent Adult Brain Tumor; Recurrent Adult Primary Liver Cancer; Recurrent Adult Soft Tissue Sarcoma; Recurrent Bladder Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Esophageal Cancer; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Gastric Cancer; Recurrent Kaposi Sarcoma; Recurrent Melanoma; Recurrent Non-small Cell Lung Cancer; Recurrent Osteosarcoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Prostate Cancer; Recurrent Rectal Cancer; Recurrent Renal Cell Cancer; Recurrent Small Cell Lung Cancer; Recurrent Uterine Sarcoma; Small Intestine Leiomyosarcoma; Stage I Colon Cancer; Stage I Rectal Cancer; Stage I Uterine Sarcoma; Stage IA Breast Cancer; Stage IA Gastric Cancer; Stage IA Ovarian Epithelial Cancer; Stage IA Ovarian Germ Cell Tumor; Stage IB Breast Cancer; Stage IB Gastric Cancer; Stage IB Ovarian Epithelial Cancer; Stage IB Ovarian Germ Cell Tumor; Stage IC Ovarian Epithelial Cancer; Stage IC Ovarian Germ Cell Tumor; Stage II Breast Cancer; Stage II Uterine Sarcoma; Stage IIA Colon Cancer; Stage IIA Gastric Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIA Ovarian Epithelial Cancer; Stage IIA Ovarian Germ Cell Tumor; Stage IIA Rectal Cancer; Stage IIB Colon Cancer; Stage IIB Esophageal Cancer; Stage IIB Gastric Cancer; Stage IIB Melanoma; Stage IIB Non-small Cell Lung Cancer; Stage IIB Ovarian Epithelial Cancer; Stage IIB Ovarian Germ Cell Tumor; Stage IIB Rectal Cancer; Stage IIC Colon Cancer; Stage IIC Melanoma; Stage IIC Ovarian Epithelial Cancer; Stage IIC Ovarian Germ Cell Tumor; Stage IIC Rectal Cancer; Stage III Uterine Sarcoma; Stage IIIA Breast Cancer; Stage IIIA Colon Cancer; Stage IIIA Esophageal Cancer; Stage IIIA Gastric Cancer; Stage IIIA Melanoma; Stage IIIA Non-small Cell Lung Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Ovarian Germ Cell Tumor; Stage IIIA Rectal Cancer; Stage IIIB Breast Cancer; Stage IIIB Colon Cancer; Stage IIIB Esophageal Cancer; Stage IIIB Gastric Cancer; Stage IIIB Melanoma; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Ovarian Germ Cell Tumor; Stage IIIB Rectal Cancer; Stage IIIC Breast Cancer; Stage IIIC Colon Cancer; Stage IIIC Esophageal Cancer; Stage IIIC Gastric Cancer; Stage IIIC Melanoma; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Ovarian Germ Cell Tumor; Stage IIIC Rectal Cancer; Stage IV Bladder Cancer; Stage IV Esophageal Cancer; Stage IV Gastric Cancer; Stage IV Melanoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Prostate Cancer; Stage IV Renal Cell Cancer; Stage IV Uterine Sarcoma; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sirolimus; Other: laboratory biomarker analysis; Biological: DEC-205-NY-ESO-1 fusion protein vaccine
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012 - Condition: Alopecia Areata
Interventions: Drug: vytorin; Drug: vytorin
Sponsors: University of Miami; University of Miami
Recruiting - verified January 2012 - Conditions: Skin and Subcutaneous Tissue Bacterial Infections; Wound Infection; Cutaneous Abscess; Burn Infection; Cellulitis
Intervention: Drug: AFN-12520000
Sponsors: Affinium Pharmaceuticals, Ltd; Affinium Pharmaceuticals, Ltd
Recruiting - verified May 2012 - Condition: Tinea Pedis
Interventions: Drug: Oxiconazole Nitrate Cream 1%; Drug: Oxiconazole Nitrate Cream 1% (Oxistat®); Drug: Placebo
Sponsors: Taro Pharmaceuticals USA; Taro Pharmaceuticals USA
Recruiting - verified January 2012 - Condition: Pediculosis
Interventions: Drug: Ha44; Drug: Ha44 Placebo; Drug: Moxifloxacin Placebo; Drug: Moxifloxacin
Sponsors: Hatchtech Pty Ltd; Hatchtech Pty Ltd
Not yet recruiting - verified January 2012 - Condition: Psoriasis
Intervention: Drug: etanercept
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention: Behavioral: AIM materials and assessments
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Brown University; Weill Medical College of Cornell University
Recruiting - verified March 2012 - Condition: Metastatic Breast Cancer
Interventions: Biological: OPT-822/OPT-821; Biological: Phosphate Buffer Saline (PBS)
Sponsors: Optimer Pharmaceuticals; Optimer Biotechnology, Inc.
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Behavioral: Exercise; Behavioral: Surgical preparation program
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Yale University; Susan G. Komen Breast Cancer Foundation
Recruiting - verified January 2012 - Condition: Breast Cancer
Intervention:
Sponsors: Thomas Jefferson University; Thomas Jefferson University
Recruiting - verified January 2012 - Condition: Breast Cancer
Intervention: Drug: trastuzumab emtansine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rosacea
Interventions: Drug: Metronidazole Topical Gel 1%; Drug: Metronidazole Topical Gel 1% (Metrogel); Drug: Placebo
Sponsors: Taro Pharmaceuticals USA; Taro Pharmaceuticals USA
Recruiting - verified January 2012 - Conditions: Lupus Erythematosus; Photosensitivity
Intervention: Other: Phototesting
Sponsors: University of Pennsylvania; University of Pennsylvania
Recruiting - verified January 2012 - Condition: Psoriasis
Intervention: Drug: Ustekinumab
Sponsors: University of California, San Francisco; University of California, San Francisco
Not yet recruiting - verified January 2012 - Conditions: Chemotherapy-induced Neutropenia; Breast Cancer
Interventions: Drug: LA-EP2006; Drug: Peg-Filgrastim
Sponsors: Sandoz; Sandoz
Recruiting - verified January 2012 - Condition: Vitiligo
Interventions: Drug: Simvastatin; Drug: Placebo
Sponsors: University of Massachusetts, Worcester; University of Massachusetts, Worcester
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention: Radiation: External Beam Partial-Breast Irradiation
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital
Recruiting - verified May 2012 - Condition: Cutaneous Lupus Erythematosus
Intervention:
Sponsors: University of Pennsylvania; University of Pennsylvania
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Behavioral: Exercise Program; Behavioral: Telephone Counseling Calls; Behavioral: Standard Care; Behavioral: Health Behavior Survey
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: Veliparib; Drug: Temozolomide; Drug: Carboplatin; Drug: Paclitaxel; Drug: Placebo
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Condition: Breast Cancer
Intervention: Device: Optical Coherence Tomography
Sponsors: Diagnostic Photonics, Inc.; Diagnostic Photonics, Inc.; University of Illinois
Not yet recruiting - verified March 2012 - Condition: Cutaneous Lupus Erythematosus
Intervention: Dietary Supplement: vitamin D
Sponsors: Emory University; Emory University; Dermatology Foundation
Recruiting - verified January 2012 - Condition: Psoriasis
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Immunex Corporation
Recruiting - verified February 2012 - Condition: Acne Vulgaris
Interventions: Drug: Adapalene + benzoyl peroxide samples; Drug: Adapalene + benzoyl peroxide from standard tube
Sponsors: Wake Forest University; Wake Forest University; Galderma Laboratories, L.P.
Recruiting - verified January 2012 - Conditions: Breast Cancer; Invasive Adenocarcinoma of the Breast
Interventions: Procedure: Cryoablation; Biological: Ipilimumab
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012 - Conditions: Breast Cancer; Young Women Breast Cancer; Pregnancy Associated Breast Cancer
Intervention:
Sponsors: University of Colorado, Denver; University of Colorado, Denver
Recruiting - verified December 2011 - Condition: Breast Cancer
Interventions: Behavioral: Baseline Fitness Test; Behavioral: Questionnaires; Behavioral: Individualized Exercise Program; Behavioral: Written Materials
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Lung Cancer; Breast Cancer; Colorectal Cancer; Cholangiocarcinoma; Solid Tumors
Intervention: Drug: BKM120
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention:
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; Department of Defense
Not yet recruiting - verified September 2011 - Condition: Acne Vulgaris
Interventions: Drug: Placebo; Drug: gevokizumab; Drug: gevokizumab
Sponsors: XOMA (US) LLC; XOMA (US) LLC
Recruiting - verified December 2011 - Conditions: Psoriasis; Skin Diseases; Skin Diseases, Papulosquamous
Interventions: Drug: Placebo; Drug: LY3009104
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Incyte Corporation
Recruiting - verified May 2012 - Condition: Complicated Skin and Soft Tissue Infection
Interventions: Drug: Ceftaroline fosamil; Drug: Vancomycin; Drug: Aztreonam
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Not yet recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: TAC chemotherapy; Drug: TC chemotherapy; Drug: Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy; Drug: TCH chemotherapy
Sponsors: Agendia; Agendia; University of South Florida; University of Miami
Recruiting - verified January 2012 - Condition: White Spot Lesions
Interventions: Device: Vanish varnish; Device: Oral B Minute-Gel
Sponsors: 3M; 3M; University of Tennessee Health Science Center
Recruiting - verified February 2012 - Conditions: Vulvodynia; Dyspareunia; Breast Cancer; Menopause
Intervention: Drug: Topical liquid lidocaine
Sponsors: Oregon Health and Science University; Oregon Health and Science University
Recruiting - verified February 2012 - Condition: Improvement in Distention/Bloating Scale ≥ 0.14 at the End of 4 Weeks.
Intervention: Drug: Lactobacillus
Sponsors: University of Michigan; University of Michigan
Not yet recruiting - verified December 2011 - Conditions: Breast Cancer; Obesity
Intervention: Behavioral: aerobic exercise
Sponsors: West Virginia University; West Virginia University
Recruiting - verified February 2012 - Condition: Atopic Dermatitis
Intervention: Drug: Fluzone® Intradermal (Sanofi Pasteur Inc.)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2011 - Condition: Angiotensin-converting Enzyme (ACE) Inhibitor-associated Angioedema
Interventions: Drug: HOE-140; Other: Placebo
Sponsors: Vanderbilt University; Vanderbilt University; University of California, San Diego; Massachusetts General Hospital; University of California, Los Angeles
Recruiting - verified April 2012 - Conditions: Cancer Survivor; Human Papilloma Virus Infection
Interventions: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Other: questionnaire administration; Other: laboratory biomarker analysis; Other: survey administration; Other: medical chart review
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Not yet recruiting - verified December 2011 - Conditions: Mestatic Melanoma; Skin Cancer
Interventions: Drug: Fludarabine; Drug: Cycolphosphamide; Drug: Aldesleukin; Drug: MART-1 Reactive CD8+ PBL
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: HKI-272; Drug: HKI-272; Procedure: Surgical Resection
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Translational Breast Cancer Research Consortium
Recruiting - verified February 2012 - Condition: Papulopustular Rosacea (PPR)
Interventions: Drug: CD5024; Drug: Azelaic acid 15% Gel
Sponsors: Galderma; Galderma
Recruiting - verified April 2012 - Condition: Papulopustular Rosacea
Interventions: Drug: CD5024; Drug: Azelaic acid 15% Gel
Sponsors: Galderma; Galderma
Recruiting - verified April 2012 - Conditions: Breast Neoplasms; Endocrine Breast Diseases; Neoplasm Metastasis
Interventions: Drug: letrozole; Drug: lapatinib; Drug: everolimus
Sponsors: University of Maryland; University of Maryland; Novartis Pharmaceuticals; GlaxoSmithKline
Not yet recruiting - verified December 2011 - Conditions: Locally Recurrent Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: NKTR-102; Drug: Treatment of Physician's Choice (TPC)
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified April 2012 - Condition: Hidradenitis Suppurativa
Intervention: Drug: anakinra
Sponsors: University of California, San Francisco; University of California, San Francisco
Not yet recruiting - verified March 2012 - Conditions: Poikiloderma of Civatte; Dyschromia; Pigmentation Disorders; Telangiectasia; Photosensitivity Disorders
Intervention: Device: 532 nm KTP laser
Sponsors: Cutera Inc.; Cutera Inc.
Recruiting - verified December 2011 - Condition: Breast Cancer
Intervention: Other: 3D HI and SHI of ultrasound contrast agent
Sponsors: Thomas Jefferson University; Thomas Jefferson University; National Cancer Institute (NCI); Lantheus Medical Imaging; University of California, San Diego
Recruiting - verified December 2011 - Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab; Drug: Aromatase Inhibitor; Drug: Induction Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Radiation Toxicity; Recurrent Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Interventions: Dietary Supplement: alkaline water; Dietary Supplement: distilled water; Radiation: external beam radiation therapy (EBRT)
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Breast Cancer
Intervention: Behavioral: Individualized manualized Ayurvedic intervention
Sponsors: University of California, San Francisco; University of California, San Francisco; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified March 2012 - Condition: Plaque Psoriasis
Intervention: Drug: Apo805K1
Sponsors: ApoPharma; ApoPharma
Recruiting - verified January 2012 - Condition: Leishmaniasis
Interventions: Biological: LEISH-F3 + GLA-SE; Biological: LEISH-F3 + GLA-SE; Biological: LEISH-F3 alone
Sponsors: Infectious Disease Research Institute; Infectious Disease Research Institute
Recruiting - verified January 2012 - Condition: Psoriasis
Interventions: Drug: CNTO 1959 (5 mg); Drug: CNTO 1959 (15 mg); Drug: CNTO 1959 (50 mg); Drug: CNTO 1959 (100 mg); Drug: CNTO 1959 (200 mg); Drug: Adalimumab; Drug: Placebo to CNTO 1959 (100 mg)
Sponsors: Janssen Inc.; Janssen Inc.
Recruiting - verified February 2012 - Conditions: Male Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: mifepristone; Drug: placebo; Drug: nab-paclitaxel
Sponsors: University of Chicago; Rita Nanda
Recruiting - verified December 2011 - Condition: Onychomycosis
Intervention: Drug: Terbinafine HCl
Sponsors: Nitric BioTherapeutics, Inc; Nitric BioTherapeutics, Inc
Recruiting - verified December 2011 - Conditions: Breast Cancer; Gastrointestinal Cancer
Intervention: Behavioral: questionnaire and interview
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012 - Conditions: Breast Cancer; Colon Cancer; Lung Cancer; Neuroblastoma; Testicular Cancer
Interventions: Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions; Behavioral: Focus Group Sessions
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012 - Conditions: Metastatic Solid Tumor; Breast Cancer; Ovarian Cancer
Intervention: Drug: Rucaparib
Sponsors: Clovis Oncology, Inc.; Clovis Oncology, Inc.
Recruiting - verified May 2012 - Conditions: Head and Neck Neoplasms; Lung Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms
Interventions: Drug: Tetrahydrouridine (THU); Drug: [F-18]-5-FLUORO-2'-DEOXYCYTIDINE
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Drug: AMG 479; Drug: Trastuzumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Amgen
Not yet recruiting - verified November 2011 - Condition: HER2 Negative Breast Cancer
Interventions: Biological: NeuVax vaccine; Biological: Leukine (sargramostim, GM-CSF) and water for injection
Sponsors: Galena Biopharma, Inc.; Galena Biopharma, Inc.
Recruiting - verified May 2012 - Condition: Acne Vulgaris
Intervention: Drug: RA-18C3
Sponsors: XBiotech, Inc.; XBiotech, Inc.
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Device: MammaPrint; Device: BluePrint; Device: TargetPrint; Device: TheraPrint
Sponsors: Agendia; Agendia
Recruiting - verified April 2012 - Condition: Psoriasis
Interventions: Drug: 80mg LY2439821 Dosing Regimen; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Arthritis, Psoriatic
Interventions: Biological: Placebo matching BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified January 2012 - Condition: Malignant Tumor
Intervention: Device: Novilase Interstitial Laser Therapy
Sponsors: Novian Health Inc.; Novian Health Inc.
Recruiting - verified April 2012 - Conditions: Breast Cancer; Brain Metastases
Interventions: Drug: GRN1005; Drug: Trastuzumab
Sponsors: Geron Corporation; Geron Corporation
Recruiting - verified May 2012 - Condition: Actinic Keratosis
Interventions: Drug: Broad Area ALA 1-hour incubation; Drug: Broad Area ALA 2-hr incubation; Drug: broad area ALA 3-hour incubation; Drug: Spot application ALA 2 hour incubation; Drug: Vehicle PDT
Sponsors: DUSA Pharmaceuticals, Inc.; DUSA Pharmaceuticals, Inc.
Recruiting - verified February 2012 - Conditions: Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Dietary Supplement: omega-3 fatty acid; Other: placebo; Procedure: quality-of-life assessment; Procedure: assessment of therapy complications; Procedure: magnetic resonance imaging; Other: laboratory biomarker analysis; Other: questionnaire administration
Sponsors: Ohio State University Comprehensive Cancer Center; Maryam Lustberg; Cancer and Leukemia Group B; Alliance
Recruiting - verified May 2012 - Condition: Hidradenitis Suppurativa (HS)
Interventions: Biological: adalimumab; Biological: placebo; Biological: adalimumab
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Condition: Hidradenitis Suppurativa (HS)
Interventions: Biological: adalimumab; Biological: placebo; Biological: adalimumab
Sponsors: Abbott; Abbott
Recruiting - verified December 2011 - Condition: Breast Cancer
Interventions: Drug: Vitamin D3; Drug: Vitamin D3
Sponsors: Stanford University; Robert Carlson
Recruiting - verified December 2011 - Condition: Atopic Dermatitis
Intervention: Drug: Fluocinonide cream
Sponsors: Wake Forest University; Wake Forest University; Medicis Pharmaceutical Corporation
Recruiting - verified November 2011 - Condition: Primary Invasive Breast Cancer
Intervention:
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Other: EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire; Other: EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire; Other: EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; The City College of New York; Ralph Lauren Center for Cancer Care and Prevention; Lincoln Hospital
Recruiting - verified November 2011 - Conditions: Skin Laxity; Wrinkles
Intervention:
Sponsors: Ulthera, Inc; Ulthera, Inc
Recruiting - verified January 2012 - Conditions: Breast Cancer; Neurocognitive Impairment; Quality of Life
Intervention: Other: Neurocognitive impairment observation
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; National Institute of Nursing Research (NINR)
Not yet recruiting - verified March 2012 - Condition: Cutaneous Lupus Erythematosus
Interventions: Drug: PD-0360324; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Metformin; Other: Placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Susan G. Komen Breast Cancer Foundation
Not yet recruiting - verified February 2012 - Condition: Breast Cancer
Intervention:
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified November 2011 - Conditions: Atopic Dermatitis; Eczema Herpeticum
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Condition: Discoid Lupus
Interventions: Drug: CC-930; Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified March 2012 - Condition: Psoriasis Vulgaris
Interventions: Drug: CT327 0.05%; Drug: CT327 0.1%; Drug: CT327 0.5%; Drug: Placebo
Sponsors: Creabilis SA; Creabilis SA
Recruiting - verified May 2012 - Conditions: Systemic Sclerosis; Ulcers
Interventions: Drug: macitentan 3mg; Drug: macitentan 10mg; Drug: placebo
Sponsors: Actelion; Actelion
Recruiting - verified May 2012 - Conditions: Systemic Sclerosis; Ulcers
Interventions: Drug: macitentan 3mg; Drug: macitentan 10mg; Drug: placebo
Sponsors: Actelion; Actelion
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention:
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Institutes of Health (NIH); National Institute on Aging (NIA)
Recruiting - verified November 2011 - Condition: Basal Cell Carcinomas
Intervention: Device: PulseCure pulse generator and Derm-pulse electrode
Sponsors: Children's Hospital & Research Center Oakland; Children's Hospital & Research Center Oakland
Recruiting - verified October 2011 - Conditions: Breast Cancer; Breast Neoplasm
Intervention: Drug: Pazopanib
Sponsors: University of California, San Francisco; Hope Rugo, MD; GlaxoSmithKline
Recruiting - verified April 2012 - Conditions: Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation; Other: questionnaire administration
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012 - Condition: Epidermolysis Bullosa
Intervention: Procedure: Grafting of Autologous Cultured Revertant Keratinocytes
Sponsors: Stanford University; Stanford University
Recruiting - verified October 2011 - Conditions: Osteoarthritis; Rheumatoid Arthritis; Ankylosing Spondylitis; Other Arthritic Conditions (e.g., Psoriatic Arthritis)
Intervention: Behavioral: painACTION: Arthritis
Sponsors: Inflexxion, Inc.; Inflexxion, Inc.
Recruiting - verified October 2011 - Condition: Keratosis, Actinic
Interventions: Drug: Aminolevulinic Acid PDT (ALA); Drug: Vehicle PDT (VEH)
Sponsors: DUSA Pharmaceuticals, Inc.; DUSA Pharmaceuticals, Inc.
Recruiting - verified November 2011 - Condition: HIV Infection
Intervention:
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)
Recruiting - verified November 2011 - Conditions: Adult Acute Lymphoblastic Leukemia; Adult Acute Myeloid Leukemia; Adult Burkitt Lymphoma; Adult Diffuse Large Cell Lymphoma; Adult Diffuse Mixed Cell Lymphoma; Adult Diffuse Small Cleaved Cell Lymphoma; Adult Hodgkin Lymphoma; Adult Immunoblastic Large Cell Lymphoma; Adult Lymphoblastic Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Breast Cancer; Chronic Eosinophilic Leukemia; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Cutaneous T-cell Non-Hodgkin Lymphoma; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3 Follicular Lymphoma; Malignant Testicular Germ Cell Tumor; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Multiple Myeloma; Mycosis Fungoides/Sezary Syndrome; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neutropenia; Nodal Marginal Zone B-cell Lymphoma; Ovarian Epithelial Cancer; Ovarian Germ Cell Tumor; Plasma Cell Neoplasm; Poor Prognosis Metastatic Gestational Trophoblastic Tumor; Primary Myelofibrosis; Prolymphocytic Leukemia; Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma
Intervention: Drug: cefepime hydrochloride
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Conditions: Cognitive/Functional Effects; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Procedure: ultrasound imaging; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment; Procedure: magnetic resonance imaging
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Scar
Interventions: Drug: Dysport (abobotulinumtoxinA); Drug: Bacteriostatic 0.9% Sodium Chloride (vehicle)
Sponsors: AboutSkin Dermatology and DermSurgery, PC; AboutSkin Dermatology and DermSurgery, PC; University Hospitals of Cleveland; Medicis Pharmaceutical Corporation
Recruiting - verified January 2012 - Condition: Hereditary Angioedema
Intervention: Drug: Icatibant
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Shire Human Genetic Therapies, Inc.
Recruiting - verified April 2012 - Condition: Subjects With Advanced Solid Tumors (Including, But Not Limited to Gastric, Head and Neck, NSCLC, Colon, Mesothelioma and Triple Negative Breast Cancer).
Interventions: Drug: ABT-700; Drug: ABT-700 plus erlotinib; Drug: ABT-700 plus Oxaliplatin and Capecitabine
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Condition: Onychomycosis
Intervention: Device: Diode Laser Treatment
Sponsors: ConBio, a Cynosure Company; ConBio, a Cynosure Company
Recruiting - verified October 2011 - Condition: Non-Melanoma Skin Cancer
Intervention:
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012 - Conditions: Breast Neoplasms; Breast Cancer; Breast Tumors; Cancer of the Breast; Neoplasms, Breast; Tumors, Breast
Interventions: Drug: Eribulin; Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: Emory University; Emory University; Eisai Inc.
Recruiting - verified December 2011 - Condition: Breast Cancer
Intervention: Drug: GSK1120212
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; GlaxoSmithKline
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention:
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI); North Carolina TraCS Institute
Not yet recruiting - verified December 2011 - Conditions: Locally Advance Breast Cancer (LABC); Metastatic Breast Cancer (MBC)
Interventions: Drug: BEZ235 + Trastuzumab Phase l/Phase ll); Drug: Lapatinib + Capecitabine (Phase II)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Colorectal Cancer; Squamous Cell Head and Neck Cancer; Non-small Cell Lung Cancer; Triple Negative Breast Cancer; Other Tumors With EGFR Dependence
Interventions: Drug: MM-121 (SAR256212); Drug: Irinotecan; Drug: Cetuximab
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi-Aventis
Recruiting - verified January 2012 - Condition: Human Papilloma Virus Infection
Intervention:
Sponsors: Gen-Probe, Incorporated; Gen-Probe, Incorporated
Not yet recruiting - verified October 2011 - Condition: Diabetic Foot Ulcer
Interventions: Device: SECONDARY dressing gauze and tape; Procedure: debridement, irrigation; Device: Dermagraft™; Device: Oasis™
Sponsors: VA Northern California Health Care System; VA Northern California Health Care System
Recruiting - verified October 2011 - Conditions: Metastatic Melanoma; Skin Cancer
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Young TIL
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Breast Cancer
Interventions: Other: educational intervention; Other: questionnaire administration; Other: counseling intervention; Other: survey administration; Procedure: quality-of-life assessment
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Breast Cancer; Microbiota; Estrogens
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011 - Conditions: Autoimmune/Connective Tissue Diseases; Immune System Diseases; Behcet's Disease
Interventions: Drug: Anakinra; Other: Placebo
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified August 2011 - Conditions: Healthy, no Evidence of Disease; Non-melanomatous Skin Cancer
Interventions: Dietary Supplement: cholecalciferol; Genetic: gene expression analysis; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); University of Arizona; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Conditions: Bladder Cancer; Colorectal Cancer; Endometrial Cancer; Kidney Cancer; Skin Cancer; Uterus Cancer
Intervention: Behavioral: Health and Diet Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Inoperable Locally Advanced Breast Cancer; Metastatic Breast Cancer (MBC)
Intervention: Drug: BEZ235 + Paclitaxel
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Breast Cancer; Ductal Carcinoma in Situ
Interventions: Device: Mammosite ML; Device: Mammosite ML
Sponsors: St. John's Mercy Research Institute, St. Louis; St. John's Mercy Research Institute, St. Louis
Recruiting - verified October 2011 - Conditions: Breast Cancer; Ovarian Cancer
Interventions: Drug: AZ2281; Drug: Carboplatin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Breast Cancer
Interventions: Radiation: 111 Indium CHX-A DTPA-Trastuzumab; Drug: 111Indium Trastuzumab
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Scleroderma
Interventions: Procedure: Rituximab sandwich regiment followed by SCT; Procedure: cyclophosphamide regiment followed by SCT
Sponsors: Northwestern University; Richard Burt, MD
Recruiting - verified April 2012 - Conditions: Breast Neoplasms; Breast Cancer
Interventions: Drug: Taxane; Drug: Taxotere; Drug: Abraxane; Drug: Ixabepilone
Sponsors: The Methodist Hospital System; The Methodist Hospital System
Recruiting - verified September 2011 - Conditions: Advanced Solid Tumors; Metastatic Breast Cancer; Metastatic Renal Cell Carcinoma
Intervention: Drug: RAD001 + BEZ235
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Breast Neoplasms; Neoplasm Metastasis
Interventions: Drug: afatinib; Drug: afatinib; Drug: Vinorelbine; Drug: Investigator's choice of treatment
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Prostate Cancer; Breast Cancer; Lung Cancer; Ovarian Cancer; Lymphoma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Not yet recruiting - verified March 2012 - Conditions: Recurrent Neuroendocrine Carcinoma of the Skin; Stage I Neuroendocrine Carcinoma of the Skin; Stage II Neuroendocrine Carcinoma of the Skin; Stage III Neuroendocrine Carcinoma of the Skin; Stage IV Neuroendocrine Carcinoma of the Skin
Interventions: Biological: interleukin-12 gene; Biological: electroporation-mediated plasmid DNA vaccine therapy; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Breast Cancer; Obesity
Interventions: Behavioral: Group phone counseling; Behavioral: Newsletter
Sponsors: University of Kansas; Christie Befort, PhD; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention: Drug: Cabozantinib
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Exelixis
Recruiting - verified January 2012 - Condition: Breast Neoplasms
Intervention: Behavioral: Decision control preference scale
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified October 2011 - Conditions: Estrogen Receptor Positive Tumor; Breast Cancer
Intervention: Drug: E7389 (eribulin mesylate) and capecitabine
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012 - Condition: Androgenetic Alopecia
Interventions: Device: TopHat 655 rejuvenation system; Device: Laser and/or Light Hair Rejuvenation System
Sponsors: Apira Science, Inc.; Apira Science, Inc.
Recruiting - verified September 2011 - Condition: Herpes Simplex Type II
Interventions: Drug: Tenofovir; Drug: placebo gel; Drug: tenofovir disoproxil fumarate (TDF); Drug: placebo tablets
Sponsors: University of Washington; University of Washington; CONRAD; Gilead Sciences
Recruiting - verified March 2012 - Conditions: Colorectal Cancer With Hepatic Metastases; Pancreas Cancer With Hepatic Metastase; Gastric Cancer With Hepatic Metastase; Breast Cancer With Hepatic Metastase; Ovarian Cancer With Hepatic Metastase
Intervention: Drug: TKM-080301
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Psoriasis
Interventions: Behavioral: Standard nurse education; Behavioral: Additional nurse education
Sponsors: Wake Forest University; Wake Forest University
Recruiting - verified September 2011 - Condition: Breast Cancer
Interventions: Drug: entinostat; Drug: lapatinib ditosylate; Genetic: protein expression analysis; Other: circulating tumor cell analysis; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Pressure Ulcers; Spinal Cord Injury
Interventions: Drug: HP011-101 (Xenaderm Ointment); Drug: Standard Care
Sponsors: Healthpoint; Healthpoint
Recruiting - verified October 2011 - Condition: Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Interventions: Drug: MEDI-573; Drug: Aromatase Inhibitor
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2012 - Conditions: Major Depressive Disorder; Attention-deficit Hyperactivity Disorder (ADHD)
Intervention:
Sponsors: Wake Forest University Baptist Medical Center; Wake Forest University Baptist Medical Center
Recruiting - verified September 2011 - Condition: Distal and Lateral Subungual Onychomycosis
Interventions: Drug: Luliconazole Solution, 10%; Drug: Vehicle Solution
Sponsors: Topica Pharmaceuticals; Topica Pharmaceuticals
Not yet recruiting - verified February 2012 - Condition: Kawasaki Disease
Intervention: Drug: Atorvastatin
Sponsors: University of California, San Diego; University of California, San Diego
Not yet recruiting - verified September 2011 - Condition: Breast Cancer
Intervention:
Sponsors: Hologic, Inc.; Hologic, Inc.
Recruiting - verified September 2011 - Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: GDC-0941; Drug: GDC-0980; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention:
Sponsors: University of Arkansas; University of Arkansas
Recruiting - verified March 2012 - Conditions: Breast Cancer; Genitourinary Cancer; Malignant Female Reproductive System Neoplasm; Melanoma; Sarcoma
Intervention: Procedure: Punch Biopsy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Department of Defense
Recruiting - verified March 2012 - Condition: Lymphedema
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Sturge-Weber Syndrome
Intervention:
Sponsors: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; National Institutes of Health (NIH); University of California, San Francisco; National Institute of Neurological Disorders and Stroke (NINDS); Duke University; Children's Hospital of Michigan; Baylor College of Medicine; Texas Children's Hospital; Wills Eye; Nationwide Children's Hospital
Recruiting - verified February 2012 - Conditions: Healthy Volunteers; Atopic Dermatitis; Netherton Syndrome
Interventions: Drug: BPR277 ointment (controlled application); Drug: Placebo (Vehicle); Drug: BPR277 ointment; Drug: Placebo (Vehicle); Drug: BPR277; Drug: Placebo (Vehicle)
Sponsors: Novartis; Novartis
Recruiting - verified November 2011 - Condition: Breast Cancer
Interventions: Biological: Ramucirumab (IMC-1121B); Drug: Eribulin
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified May 2012 - Conditions: Arthritis; Spondylitis, Ankylosing
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified April 2012 - Condition: Acne Vulgaris
Interventions: Drug: Fixed Combination dapsone/adapalene Formulation A Gel; Drug: Fixed Combination dapsone/adapalene Formulation B Gel; Drug: dapsone 5% gel; Drug: adapalene 0.3% gel
Sponsors: Allergan; Allergan
Not yet recruiting - verified May 2012 - Condition: Rosacea
Interventions: Drug: oral doxycycline and topical metronidazole; Drug: oral doxycycline; Drug: placebo
Sponsors: Galderma Laboratories, L.P.; Galderma Laboratories, L.P.
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Device: AeroForm Patient Controlled Tissue Expander; Procedure: Implantation of Saline Tissue Expander
Sponsors: AirXpanders, Inc.; AirXpanders, Inc.
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention: Other: Non invasive venous ultrasound
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Staphylococcal Skin Infections
Interventions: Drug: Daptomycin; Drug: Vancomycin
Sponsors: Cubist Pharmaceuticals; Cubist Pharmaceuticals
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Other: questionnaire administration; Drug: fluocinonide cream; Procedure: management of therapy complications
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Psoriatic Arthritis
Interventions: Drug: AMG 827; Drug: Placebo; Drug: AMG 827
Sponsors: Amgen; Amgen
Recruiting - verified January 2012 - Condition: Psoriasis
Intervention: Drug: AMG 557 or PLACEBO
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Conditions: Venous Disease; Venous Vascular Diseases and Syndromes; Venous Insufficiency; Venous Ulcers
Interventions: Procedure: Cryotherapy: Cooling gel wrap; Procedure: Usual care
Sponsors: Medical University of South Carolina; Medical University of South Carolina; National Institute of Nursing Research (NINR)
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Biological: trastuzumab; Drug: Neratinib
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Pfizer
Recruiting - verified March 2012 - Conditions: ER Positive, Her2 Negative Breast Cancer Patients; Triple Negative Breast Cancer Patients
Interventions: Drug: MM-121 (SAR256212) plus paclitaxel; Drug: Paclitaxel
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi-Aventis
Recruiting - verified April 2012 - Conditions: Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer
Interventions: Radiation: Radiation; Drug: Imiquimod
Sponsors: New York University School of Medicine; New York University School of Medicine; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Behavioral: Motivational Interviewing; Behavioral: Counseling
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Department of Defense
Recruiting - verified January 2012 - Conditions: Myelofibrosis; Gaucher Disease; Pulmonary Fibrosis; Hermansky-Pudlak Syndrome (HPS); Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified June 2011 - Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: anti-cancer therapy
Sponsors: Genentech; Genentech
Recruiting - verified March 2012 - Condition: Plaque-type Psoriasis
Interventions: Drug: secukinumab 150mg; Drug: secukinumab 10mg/kg i.v. regimen
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified December 2011 - Condition: Dermatitis, Atopic
Intervention:
Sponsors: Northwestern University; Northwestern University; University of California, San Diego
Recruiting - verified December 2011 - Condition: Acne Vulgaris
Interventions: Drug: clindamycin phosphate 1.2%/tretinoin 0.025% gel alone; Drug: clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
Sponsors: Zeichner, Joshua, M.D.; Zeichner, Joshua, M.D.
Recruiting - verified August 2011 - Conditions: Advanced Solid Tumors; Excluding Breast Cancer
Intervention: Drug: TKI258
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: LY2523355; Drug: Ixabepilone; Drug: pegfilgrastim; Drug: filgrastim
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Actinic Keratosis
Interventions: Drug: Imiquimod cream 3.75%; Drug: Placebo cream
Sponsors: Medicis Global Service Corporation; Medicis Global Service Corporation
Recruiting - verified April 2012 - Condition: Pancreatic Cancer, Metastatic
Interventions: Drug: Gemcitabine, Erlotinib, OSI-906; Drug: Gemcitabine, Erlotinib
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Not yet recruiting - verified May 2012 - Condition: Systemic Scleroderma
Interventions: Procedure: peripheral blood stem cell transplantation; Drug: cyclophosphamide; Biological: anti-thymocyte globulin; Other: questionnaire administration; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment; Biological: filgrastim; Procedure: autologous hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012 - Condition: Keloid
Intervention: Biological: bevacizumab
Sponsors: Tirgan, Michael H., M.D.; Tirgan, Michael H., M.D.
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention:
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University
Recruiting - verified August 2011 - Conditions: Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Invasive Ductal Breast Carcinoma; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer
Interventions: Drug: zoledronic acid; Other: laboratory biomarker analysis; Procedure: therapeutic conventional surgery
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Other: Arm A; Behavioral: Arm B
Sponsors: Columbia University; Columbia University; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Diabetic Foot Ulcers; Diabetic Foot Wounds
Interventions: Biological: Santyl; Procedure: Standard Care
Sponsors: Healthpoint; Healthpoint
Recruiting - verified May 2012 - Conditions: Inflammatory Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Mucinous Ductal Breast Carcinoma; Papillary Ductal Breast Carcinoma; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Tubular Ductal Breast Carcinoma
Intervention: Radiation: External beam radiation therapy
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Conditions: Breast Cancer; Cognitive/Functional Effects; Depression; Fatigue; Pain; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Skin Reactions Secondary to Radiation Therapy
Interventions: Genetic: DNA analysis; Genetic: gene expression analysis; Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: adjuvant therapy; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment; Radiation: 3-dimensional conformal radiation therapy; Radiation: breast irradiation; Radiation: external beam radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Atopic Dermatitis; Eczema Herpeticum; Herpes Simplex Infections; Eczema Vaccinatum
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Jewish Health; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2011 - Condition: Rosacea
Interventions: Drug: Topical aminocaproic acid (ACA) mixed with Vanicream; Drug: Vehicle cream
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified April 2011 - Condition: Melanoma
Intervention: Other: recMAGE-A3 + AS15 ASCI
Sponsors: University of Virginia; Craig L Slingluff, Jr; GlaxoSmithKline
Recruiting - verified August 2011 - Condition: Moderate to Severe Plaque-type Psoriasis
Interventions: Biological: secukinumab 150 mg; Drug: If disease relapses patient is treated with secukinumab 150 mg. If disease does not relapse patient is treated with placebo; Biological: secukinumab 300 mg; Biological: If disease relapses patient is treated with secukinumab 300 mg. If disease does not relapse patient is treated with placebo.
Sponsors: Novartis; Novartis
Recruiting - verified April 2012 - Conditions: Hepato/Renal Fibrocystic Disease; Autosomal Recessive Polycystic Kidney Disease; Joubert Syndrome; Bardet Biedl Syndrome; Meckel-Gruber Syndrome; Congenital Hepatic Fibrosis; Caroli Syndrome; Oro-Facial-Digital Syndrome Type I; Nephronophithisis; Glomerulocystic Kidney Disease
Intervention:
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified September 2011 - Conditions: Hypohidrotic Ectodermal Dysplasia; X-Linked Hypohidrotic Ectodermal Dysplasia
Intervention:
Sponsors: Edimer Pharmaceuticals; Edimer Pharmaceuticals
Recruiting - verified August 2011 - Condition: Breast Cancer
Intervention: Radiation: Accelerated partial breast irradiation
Sponsors: Brown University; Jaroslaw Hepel; The Miriam Hospital; Rhode Island Hospital
Recruiting - verified May 2012 - Condition: Vitiligo Vulgaris
Intervention:
Sponsors: St. Luke's-Roosevelt Hospital Center; St. Luke's-Roosevelt Hospital Center
Recruiting - verified March 2011 - Condition: Metastatic Breast Cancer
Interventions: Drug: eribulin mesylate; Drug: eribulin mesylate; Drug: eribulin mesylate, trastuzumab
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Eisai Inc.
Recruiting - verified March 2012 - Condition: Breast Carcinoma
Intervention:
Sponsors: New Hanover Regional Medical Center; New Hanover Regional Medical Center; National Cancer Institute (NCI); Coastal Carolina Radiation Oncology (CCRO)
Recruiting - verified August 2011 - Condition: Metastatic Breast Cancer
Interventions: Drug: fresolimumab (GC1008); Drug: fresolimumab (GC1008); Radiation: Radiation Therapy
Sponsors: New York University School of Medicine; New York University School of Medicine; University of California, Los Angeles
Recruiting - verified May 2012 - Conditions: Unspecified Adult Solid Tumor - Protocol Specific; Breast Cancer - Female
Interventions: Drug: Pazopanib; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI); GlaxoSmithKline
Recruiting - verified September 2011 - Condition: Breast Cancer
Intervention: Procedure: Radiofrequency Ablation
Sponsors: University of Kansas; University of Kansas; Angiodynamics, Inc.
Recruiting - verified October 2011 - Condition: Polymyalgia Rheumatica (PMR)
Intervention: Drug: Tocilizumab
Sponsors: Hospital for Special Surgery, New York; Hospital for Special Surgery, New York; Genentech
Recruiting - verified January 2012 - Conditions: Venous Ulcer; Infection
Interventions: Device: Restore Calcium Alginate Dressing; Device: AquaCel Ag Wound Dressing
Sponsors: Hollister Wound Care LLC; Hollister Wound Care LLC
Recruiting - verified November 2011 - Conditions: Infertility; Breast Cancer
Intervention: Procedure: Random Peri-Areolar Fine Needle Aspiration (RPFNA)
Sponsors: University of Kansas; University of Kansas
Recruiting - verified July 2011 - Condition: Breast Neoplasms
Interventions: Behavioral: prosocial online support group; Behavioral: Standard Online Support Group
Sponsors: Temple University; Temple University; Cancer Support Community
Not yet recruiting - verified July 2011 - Condition: Psoriatic Arthritis
Interventions: Biological: Secukinumab (75 mg); Biological: Secukinumab (150 mg); Biological: Placebo Comparator
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in Situ; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer
Interventions: Drug: diindolylmethane; Other: placebo; Other: questionnaire administration; Procedure: digital mammography; Procedure: magnetic resonance imaging; Other: biomarker analysis of blood and urine
Sponsors: University of Arizona; University of Arizona; National Cancer Institute (NCI)
Recruiting - verified May 2011 - Condition: HER-2 Positive Breast Cancer
Interventions: Drug: eribulin; Drug: carboplatin; Drug: trastuzumab
Sponsors: ACORN Research, LLC; ACORN Research, LLC; Eisai Inc.
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Device: Visica 2™ Treatment System; Procedure: Cryoablation; Procedure: Surgical Resection
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified January 2012 - Conditions: Fungal Infections; APECED; Chronic Mucocutaneous Candidiasis; Fungal Immunopathogenesis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2012 - Condition: Hypohidrotic Ectodermal Dysplasia
Intervention:
Sponsors: Edimer Pharmaceuticals; Edimer Pharmaceuticals
Recruiting - verified June 2011 - Condition: Atopic Dermatitis
Interventions: Behavioral: Weekly Internet survey; Drug: Topical Triamcinolone
Sponsors: Wake Forest University; Wake Forest University
Recruiting - verified June 2011 - Condition: Hereditary Angioedema
Intervention: Drug: icatibant
Sponsors: Shire Human Genetic Therapies, Inc.; Shire Human Genetic Therapies, Inc.
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention: Device: NIR Imaging with FLARE and Mini-FLARE Imaging System
Sponsors: Beth Israel Deaconess Medical Center; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Dana-Farber Cancer Institute
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Genetic: BRCA testing and questionnaire assessments
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012 - Condition: Stage IV Breast Cancer
Intervention: Biological: Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG
Sponsors: University of Arkansas; University of Arkansas; Department of Defense
Recruiting - verified January 2012 - Conditions: Arthralgia; Breast Cancer; Pain
Interventions: Dietary Supplement: omega-3 fatty acid; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Alopecia Areata; Alopecia; Balding
Interventions: Procedure: Hair transplantation; Procedure: Hypodermic needle irritation
Sponsors: Emer, Jason, M.D.; Emer, Jason, M.D.
Recruiting - verified June 2011 - Conditions: Breast Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms
Interventions: Other: ²¹²Pb-TCMC-Trastuzumab; Biological: trastuzumab
Sponsors: Areva Med LLC; Areva Med LLC
Recruiting - verified January 2012 - Conditions: Breast Cancer; Fertility
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified February 2012 - Conditions: Cutaneous Lupus; Lupus
Interventions: Drug: AMG 557; Drug: AMG 557 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Conditions: Metastatic ER+ Her2- Breast Cancer; Postmenopausal
Interventions: Drug: Exemestane; Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane; Drug: Abiraterone acetate + Prednisone or Prednisolone
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012 - Conditions: Breast Cancer; Lymphoma
Intervention:
Sponsors: University of Rochester; University of Rochester
Recruiting - verified July 2011 - Condition: Breast Cancer
Intervention: Other: Diclofenac epolamine patch
Sponsors: Northwestern University; Northwestern University
Recruiting - verified May 2012 - Conditions: Estrogen Receptor-positive Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Interventions: Biological: therapeutic estradiol; Drug: exemestane; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay
Sponsors: University of Arizona; University of Arizona; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention:
Sponsors: University at Buffalo; University at Buffalo; Susan G. Komen Breast Cancer Foundation
Recruiting - verified June 2011 - Conditions: Diabetic Foot Ulcers; Equinus Deformity
Intervention:
Sponsors: Georgetown University; Georgetown University
Recruiting - verified January 2012 - Condition: Atopic Dermatitis
Interventions: Other: Cetaphil Restoraderm; Other: Standard of Care
Sponsors: Oregon Health and Science University; Oregon Health and Science University; Galderma
Recruiting - verified June 2011 - Condition: Venous Stasis Ulcer
Interventions: Device: Erchonia ML Scanner (MLS); Device: Inactive Erchonia ML Scanner (MLS)
Sponsors: Erchonia Corporation; Erchonia Corporation
Recruiting - verified June 2011 - Conditions: Breast Cancer; Gastrointestinal Cancer; Genitourinary Cancer; Sarcoma; Gynecologic Cancer
Interventions: Drug: Doxorubicin; Drug: Sildenafil
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University
Recruiting - verified April 2012 - Conditions: Malignant Neoplasm of the Breast; Acquired Absence of the Breast
Intervention:
Sponsors: National Center for Plastic Surgery, Virginia; National Center for Plastic Surgery, Virginia; Inova Health Care Services; Ohio State University Comprehensive Cancer Center; Walter Reed Army Medical Center; C. R. Bard
Recruiting - verified August 2011 - Condition: Breast Cancer
Intervention:
Sponsors: Duke University; Duke University; National Institutes of Health (NIH)
Recruiting - verified February 2012 - Condition: Psoriasis
Intervention: Drug: RA-18C3
Sponsors: XBiotech, Inc.; XBiotech, Inc.
Recruiting - verified April 2012 - Condition: Breast Diseases
Intervention:
Sponsors: State University of New York - Upstate Medical University; State University of New York - Upstate Medical University
Recruiting - verified December 2010 - Conditions: Wounds; Diabetes Complications; Diabetic Foot; Foot Ulcer
Intervention: Other: Online Wound Electronic Medical Record
Sponsors: New York University School of Medicine; New York University School of Medicine; Agency for Healthcare Research and Quality (AHRQ)
Recruiting - verified March 2012 - Conditions: Malignant Solid Tumour; Breast Cancer; Malignant Tumor of Colon; GIST; Ovarian Cancer
Intervention: Biological: HER-2 vaccine
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Procedure: Injection of isotope; Procedure: Axillary lymph node dissection
Sponsors: University of Kansas; University of Kansas
Recruiting - verified October 2011 - Condition: Ductal Carcinoma in Situ
Intervention: Drug: SOM 230 / Pasireotide
Sponsors: New York University School of Medicine; New York University School of Medicine
Recruiting - verified April 2012 - Conditions: Metastatic Melanoma; Skin Cancer
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Biological: Tumor Infiltrating Lymphocytes; Drug: IL-15
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Metastatic Melanoma; Skin Cancer
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Biological: Aldesleukin; Biological: Tumor Infiltrating Lymphocytes
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Ehlers Danlos Syndrome; External Hydrocephalus; Dysautonomia; Postural Orthostatic Tachycardia Syndrome; Venous Insufficiency
Intervention:
Sponsors: Genetic Disease Investigators; Genetic Disease Investigators
Recruiting - verified June 2011 - Conditions: Staphylococcal Infections; Staphylococcal Vaccines; Bacterial Infections; Staphylococcal Skin Infections
Interventions: Biological: SA4Ag vaccine low dose; Procedure: Blood draw; Procedure: Colonization swab sample; Biological: SA4Ag vaccine mid dose; Procedure: Blood sample; Procedure: Colonization swab sample; Biological: SA4Ag vaccine high dose; Procedure: Blood draw; Procedure: Colonization swab sample; Biological: Placebo; Procedure: Blood draw; Procedure: Colonization swab sample
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Urticaria; Angioedema; Hives; Swelling
Interventions: Drug: Vitamin D; Drug: Vitamin D
Sponsors: University of Nebraska; University of Nebraska
Not yet recruiting - verified June 2011 - Conditions: Breast Neoplasms; Psychology, Social
Intervention: Behavioral: Peer Support Program
Sponsors: University of California, San Francisco; University of California, San Francisco; California Breast Cancer Research Program; Circulo de Vida Cancer Support and Resource Center
Recruiting - verified January 2012 - Conditions: Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: goserelin acetate; Drug: letrozole; Drug: anastrozole; Procedure: therapeutic conventional surgery; Genetic: DNA analysis; Other: immunohistochemistry staining method; Procedure: positron emission tomography; Genetic: comparative genomic hybridization; Procedure: biopsy; Other: laboratory biomarker analysis; Drug: chemotherapy
Sponsors: Washington University School of Medicine; Washington University School of Medicine; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Device: Trident Specimen Radiography System; Device: Bioptics, Faxitron, and Full Field Digital Mammography (FFDM) Selenia
Sponsors: Levine, Gary M. , M.D.; Levine, Gary M. , M.D.; Hologic, Inc.
Recruiting - verified March 2012 - Conditions: Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Male Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer
Interventions: Drug: eribulin mesylate; Drug: carboplatin; Procedure: biopsy
Sponsors: Northwestern University; Northwestern University; Eisai Inc.
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention:
Sponsors: Bastyr University; Bastyr University; Fred Hutchinson Cancer Research Center; National Institutes of Health (NIH); National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified April 2012 - Conditions: Breast Cancer; Non-Small-Cell Lung Cancer; Glioblastoma; Other Cancers
Intervention: Drug: FPPRGD2
Sponsors: Stanford University; Stanford University
Recruiting - verified February 2012 - Conditions: Osteoporosis; Bone Diseases, Metabolic; Hip Fractures
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified January 2012 - Conditions: Breast Cancer; Metastatic Breast Cancer; HER-2 Positive Breast Cancer; ER Positive Breast Cancer
Intervention: Drug: AUY922
Sponsors: Texas Tech University Health Sciences Center; Texas Tech University Health Sciences Center
Recruiting - verified May 2012 - Conditions: Tinea Pedis; Athlete's Foot
Interventions: Drug: Econazole Nitrate Foam 1%; Drug: Vehicle Foam; Drug: Econazole Nitrate Cream 1%; Other: Placebo Cream
Sponsors: Quinnova Pharmaceuticals, Inc.; Quinnova Pharmaceuticals, Inc.; AmDerma Pharmaceuticals, LLC
Recruiting - verified May 2011 - Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: placebo; Drug: trastuzumab [Herceptin]; Drug: Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Breast International Group; Genentech
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Radiation: Photon; Radiation: 3D-Proton/Conventional plan
Sponsors: University of Florida; University of Florida
Recruiting - verified May 2012 - Conditions: HER2-positive Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: Ampligen; Biological: synthetic HER-2/neu peptide vaccine; Biological: GM-CSF; Other: laboratory biomarker analysis; Other: immunoenzyme technique
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Multiple Myeloma; Non-Hodgkin's Lymphoma; Glioblastoma Multiforme; Head and Neck Squamous Cell Cancer; Triple Negative Breast Cancer; Hormone Receptor-Positive Breast Cancer; Castration-Resistant Prostate Cancer; Ewing's Family of Sarcomas
Intervention: Drug: CC-115
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012 - Condition: Diabetic Ulcer
Intervention: Drug: AMD3100 injection + rhPDGF-BB topical
Sponsors: New York University School of Medicine; New York University School of Medicine; National Institutes of Health (NIH); Genzyme
Not yet recruiting - verified May 2011 - Conditions: Breast Cancer; Arthralgia
Interventions: Behavioral: Education and exercise intervention; Behavioral: Education and General Exercise
Sponsors: Georgetown University; Georgetown University
Recruiting - verified May 2011 - Conditions: Breast Cancer; Lymphedema
Interventions: Device: Low Level Laser Therapy; Device: Low Level Laser
Sponsors: New York University School of Medicine; New York University School of Medicine; Hunter College
Recruiting - verified January 2012 - Conditions: Tinea Pedis; Tinea Cruris; Tinea Corporis
Intervention: Drug: Product 33525
Sponsors: Tinea Pharmaceuticals; Tinea Pharmaceuticals
Recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Drug: azacitidine; Drug: entinostat; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Split Thickness Skin Graft; Skin Cancer Excision Site; Skin Graft
Intervention: Device: SNaP® Wound Care System
Sponsors: Spiracur, Inc.; Spiracur, Inc.
Recruiting - verified February 2012 - Conditions: Melanoma; Breast Neoplasms; Lobular Carcinoma
Intervention: Drug: LGK974
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Breast Cancer; Metastatic Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: Ixabepilone; Drug: Capecitabine; Drug: Motesanib
Sponsors: Thomas Jefferson University; Thomas Jefferson University; Susan G. Komen Breast Cancer Foundation; Amgen
Not yet recruiting - verified January 2012 - Condition: Sturge-Weber Syndrome
Intervention:
Sponsors: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; National Institutes of Health (NIH); University of California, San Francisco; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified February 2012 - Condition: ACE Inhibitor Induced Angioedema
Interventions: Drug: ecallantide; Drug: ecallantide; Drug: ecallantide; Drug: placebo
Sponsors: Dyax Corp.; Dyax Corp.
Recruiting - verified April 2012 - Conditions: Breast Cancer; Ovarian Cancer; Genetic Predisposition
Intervention: Behavioral: BRCA1/BRCA2 Genetic Counseling
Sponsors: University of Utah; University of Utah; National Cancer Institute (NCI); Huntsman Cancer Institute
Recruiting - verified November 2011 - Condition: Lymphedema
Intervention: Behavioral: self-monitoring of arm volume
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified June 2011 - Condition: Breast Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: anastrozole; Drug: exemestane; Drug: fulvestrant; Drug: letrozole
Sponsors: National Cancer Institute (NCI); Washington University Siteman Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Breast Neoplasms
Intervention:
Sponsors: Leo W. Jenkins Cancer Center; Leo W. Jenkins Cancer Center
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Drug: Celecoxib; Drug: Placebo; Drug: Cholecalciferol
Sponsors: University of North Dakota; University of North Dakota; Department of Defense
Recruiting - verified August 2011 - Condition: Invasive Breast Cancer
Intervention: Radiation: Proton Radiation
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified April 2011 - Conditions: Breast Cancer; Colon Cancer; Bladder Cancer
Interventions: Drug: Glycosylated Recombinant Human Interleukin-7; Biological: Diphtheria-Tetanus Vaccine; Biological: Polio Vaccine; Biological: Pneumaococcal Vaccine; Biological: Hepatitis A Vaccine; Biological: Hepatitis B Vaccine; Biological: Influenza Vaccine; Biological: PhiX 174
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Locally Advanced Solid Tumor; Metastatic Solid Tumor; Breast Cancer; Non Small Cell Lung Cancer; Melanoma; Colorectal Cancer
Intervention: Drug: MSC1936369B and SAR245409
Sponsors: EMD Serono; EMD Serono; Sanofi
Recruiting - verified April 2012 - Conditions: Breast Cancer; Metastatic Breast Cancer
Interventions: Procedure: 124 PET/CT imaging; Drug: Na134I; Drug: Tri-iodothyronine; Drug: Tri-iodothyronine
Sponsors: Stanford University; Stanford University
Recruiting - verified May 2011 - Conditions: Castration-resistant Prostate Cancer,; Metastatic Breast Cancer
Intervention: Drug: LFA102
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Estrogen Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: PI3K inhibitor BKM120; Drug: fulvestrant; Procedure: biopsy
Sponsors: Washington University School of Medicine; Washington University School of Medicine; National Cancer Institute (NCI)
Not yet recruiting - verified October 2011 - Condition: Refractory Mixed Type Melasma
Interventions: Device: Q-Switched Nd:YAG Laser (RevLite); Other: Microdermabrasion
Sponsors: ConBio, a Cynosure Company; ConBio, a Cynosure Company
Recruiting - verified August 2011 - Condition: Breast Cancer
Interventions: Drug: Gemcitabine and Carboplatin; Drug: P276-00 along with Gemcitabine and carboplatin
Sponsors: Piramal Healthcare Limited; Piramal Healthcare Limited
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Procedure: Tumor Biopsy; Other: Breast Cancer Registry
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Susan G. Komen Breast Cancer Foundation; Kellogg Company
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: Liposomal Doxorubicin; Drug: Seliciclib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institutes of Health (NIH)
Not yet recruiting - verified March 2012 - Condition: HIV Lipodystrophy
Interventions: Drug: mecasermin; Drug: Placebo control
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Behavioral: reminder letter; Behavioral: reminder call; Behavioral: Counselor Call; Behavioral: Booster reminder; Behavioral: Booster reminder; Behavioral: Booster reminder
Sponsors: University of Massachusetts, Worcester; University of Massachusetts, Worcester; Reliant Medical Group; Fallon Community Health Plan; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Marfan Syndrome; Turner Syndrome; Ehlers-Danlos Syndrome; Loeys-Dietz Syndrome; FBN1, TGFBR1, TGFBR2, ACTA2 or MYH11 Genetic Mutation; Bicuspid Aortic Valve Without Known Family History; Bicuspid Aortic Valve With Family History; Bicuspid Aortic Valve With Coarctation; Familial Thoracic Aortic Aneurysm and Dissections; Shprintzen-Goldberg Syndrome; Other Aneurysms and Dissections of the Thoracic Aorta Not Due to Trauma, <50yo; Other Congenital Heart Disease
Intervention:
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified May 2012 - Condition: Venous Ulcer
Interventions: Device: Apligraf; Other: Standard of care dressings
Sponsors: Organogenesis; Organogenesis
Recruiting - verified April 2012 - Conditions: Breast Cancer; Hot Flashes
Interventions: Drug: Z-endoxifen hydrochloride; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study; Other: questionnaire administration
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Breast Neoplasms
Interventions: Drug: Vinorelbine Weekly; Drug: Afatinib once daily (OD)
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Anal Cancer
Interventions: Drug: Tempol; Drug: 5-Fluorouracil; Drug: Mitomycin-C; Procedure: Radiation Therapy
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Metastatic Breast Cancer
Intervention: Drug: TRC105
Sponsors: Tracon Pharmaceuticals Inc.; Tracon Pharmaceuticals Inc.; Roswell Park Cancer Institute; Department of Defense
Recruiting - verified March 2012 - Condition: Her2normal
Intervention: Drug: eribulin mesylate
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified February 2012 - Conditions: Brain Cancer; Breast Cancer; Prostate Cancer
Intervention: Drug: 18F-fluoroacetate
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified December 2011 - Condition: Psoriasis
Intervention: Drug: Adalimumab
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; Abbott
Recruiting - verified September 2011 - Condition: Contact Dermatitis
Intervention: Biological: Patch Test
Sponsors: Allerderm; Allerderm
Not yet recruiting - verified March 2011 - Conditions: Metastatic Melanoma; Skin Cancer
Interventions: Drug: Aldesleukin; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Young Tumor Infiltrating Lymphocytes; Procedure: 1200 Gy Irradiation
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Breast Cancer
Interventions: Drug: PD0332991; Drug: Paclitaxel
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified February 2012 - Conditions: Sickle Cell Anemia; Sickle Cell Disease; Chronic Hemolytic Disorders
Intervention: Drug: Sodium Nitrite Cream
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012 - Condition: Breast Cancer
Intervention: Other: Weight Loss Dietary Pattern
Sponsors: Colorado State University; Colorado State University
Recruiting - verified February 2012 - Conditions: Polymyalgia Rheumatica; Inflammatory Diseases
Interventions: Drug: AIN457; Drug: ACZ885 (canakinumab); Drug: Prednisone
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention: Procedure: SPY Intra-Operative Angiography
Sponsors: Stanford University; Stanford University
Recruiting - verified July 2011 - Condition: Alopecia Totalis/Universalis
Interventions: Drug: Abatacept; Drug: Inactive infusion
Sponsors: Columbia University; Columbia University
Not yet recruiting - verified September 2011 - Condition: Breast Cancer
Intervention: Drug: AZ6244
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified March 2012 - Conditions: Breast Cancer; Gastrointestinal Cancer; Genitourinary Cancer; Leukemia; Lung Cancer
Intervention: Other: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Biosite
Recruiting - verified December 2011 - Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo/CP-690,550; Drug: Placebo/CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention: Radiation: Trastuzumab
Sponsors: Northwestern University; Northwestern University
Recruiting - verified May 2012 - Condition: Oral Herpes Simplex
Interventions: Drug: BTL TML HSV; Drug: Matching placebo
Sponsors: Beech Tree Labs, Inc.; Beech Tree Labs, Inc.; Norwich Clinical Research Associates LTD
Recruiting - verified January 2012 - Conditions: Breast Cancer; Colorectal Cancer; Prostate Cancer
Interventions: Behavioral: Standard Arm (mail/telephone); Behavioral: Internet Arm; Behavioral: Surveys and Questionnaires; Behavioral: Exercise and Diet
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Device: Alloderm; Device: Surgimend
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Condition: Rosacea
Interventions: Drug: Doxycycline; Other: Placebo
Sponsors: Galderma Laboratories, L.P.; Galderma Laboratories, L.P.
Recruiting - verified February 2012 - Conditions: Ovarian; Primary Peritoneal; Serous Carcinoma; Triple-Negative Breast; Fallopian Tube
Interventions: Drug: ABT-888 with Cyclophospharmide; Drug: Cyclophosphamide
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: HER-2 Positive Breast Cancer
Interventions: Drug: Everolimus; Drug: Vinorelbine; Drug: Trastuzumab
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Cancer Recurrence
Intervention: Behavioral: Acceptance and Commitment Therapy
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Drug: MM-302
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified November 2011 - Condition: Breast Neoplasms
Interventions: Drug: Metformin; Drug: Placebo; Behavioral: Lifestyle intervention; Behavioral: Standard printed dietary guidelines
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Other: DE-CEDM and CE-BMRI
Sponsors: GE Healthcare; GE Healthcare
Recruiting - verified January 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: BMK120; Drug: Capecitabine; Drug: BEZ235
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention: Other: MRI
Sponsors: Piedmont Healthcare; Piedmont Healthcare
Recruiting - verified June 2011 - Condition: Breast Cancer
Intervention:
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention: Drug: rosuvastatin
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Massachusetts General Hospital; National Institutes of Health (NIH)
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Other: MRI
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012 - Condition: Acne Vulgaris
Intervention: Biological: ANT-1207
Sponsors: Anterios Inc.; Anterios Inc.
Recruiting - verified January 2012 - Condition: Invasive Lobular and Ductal Carcinoma
Interventions: Radiation: Hypofractionated Whole Breast Radiation Therapy; Radiation: Intraoperative Electron Radiation Therapy
Sponsors: St. Joseph Hospital of Orange; St. Joseph Hospital of Orange
Recruiting - verified March 2012 - Condition: Fabry Disease
Intervention:
Sponsors: Baylor Research Institute; Baylor Research Institute
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Device: Garment Sleeve
Sponsors: Main Line Health; Main Line Health; Sharpe Strumia Foundation
Recruiting - verified January 2012 - Condition: Breast Cancer
Intervention: Drug: Calcitriol
Sponsors: University of Rochester; University of Rochester
Recruiting - verified August 2011 - Conditions: Basal Cell Carcinoma of the Skin; Pain; Recurrent Skin Cancer
Interventions: Drug: methyl-5-aminolevulinate hydrochloride cream; Drug: photodynamic therapy; Procedure: laser therapy
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in Situ; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer
Interventions: Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Genetic: gene expression analysis; Drug: systemic chemotherapy; Drug: tamoxifen citrate; Drug: aromatase inhibition therapy
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Diabetic Foot Ulcers
Interventions: Device: Epiflo; Other: Moist Wound Therapy
Sponsors: Ogenix Corporation; Ogenix Corporation
Recruiting - verified December 2011 - Conditions: Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer
Interventions: Drug: azacitidine; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: polymerase chain reaction; Genetic: western blotting; Genetic: nucleic acid sequencing; Procedure: therapeutic conventional surgery
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Procedure: contract-enhanced MRI; Radiation: Unilateral Adjuvant Radiation Therapy
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Carboplatin; Radiation: 3D-RT or IMRT
Sponsors: New York University School of Medicine; New York University School of Medicine
Recruiting - verified March 2012 - Conditions: Breast Cancer; Depression; Fatigue; Sleep Disorders
Interventions: Drug: metformin hydrochloride; Genetic: DNA analysis; Genetic: RNA analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: HER2-negative Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: paclitaxel; Biological: bavituximab; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: University of Arizona; University of Arizona; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Nonmalignant Breast Conditions; Breast Cancer
Interventions: Device: sodium hypochlorite (Dakins Soln); Drug: Chlorhexidine gluconate disk
Sponsors: Mayo Clinic; Mayo Clinic; University of California, San Francisco
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention: Other: Dietary fish versus omega 3 fatty acid supplement capsules
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: lapatinib ditosylate; Genetic: cytogenetic analysis; Genetic: gene expression analysis; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo/CP-690,550; Drug: Placebo/CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Pilot Study of Secondary Causes of Osteopenia/Osteoporosis in Adults With Breast and Prostate CancerConditions: Breast Cancer; Prostate Cancer; Osteopenia; Osteoporosis
Intervention:
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Drug: MK2206
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institutes of Health (NIH)
Recruiting - verified April 2012 - Conditions: Breast Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cilengitide; Drug: paclitaxel; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention: Radiation: accelerated hypofractionated radiotherapy (AHF-RT)
Sponsors: James Graham Brown Cancer Center; James Graham Brown Cancer Center; University of Louisville
Recruiting - verified December 2011 - Condition: Breast Cancer
Intervention: Device: Diffuse Optical Spectroscopy Imaging
Sponsors: University of California, Irvine; Montana Compton
Recruiting - verified December 2011 - Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast CancerCondition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Mobility Limitation
Interventions: Device: Lightweight wheelchair; Device: Skin Protection Cushion
Sponsors: University of Pittsburgh; University of Pittsburgh; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified June 2011 - Condition: Metastatic Breast Cancer
Intervention: Drug: Lapatinib and RAD-001
Sponsors: University of Kansas; University of Kansas
Recruiting - verified October 2011 - Conditions: Hormone Receptor-Positive Breast; Gynecologic; Desmoid; Hormone Receptor-Positive Neoplasms
Interventions: Drug: z-Endoxifen; Drug: [(18)F] Fluoroestradiol
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Drug: systemic chemotherapy; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Drug: pertuzumab in combination with trastuzumab and paclitaxel
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech; University of Pennsylvania
Recruiting - verified April 2012 - Conditions: Breast Neoplasms; Breast Cancer; Cancer of the Breast
Intervention: Drug: Lapatinib and Everolimus
Sponsors: Emory University; Emory University
Recruiting - verified January 2012 - Conditions: Breast Neoplasms; HER2 Protein, Human; Geriatric Health Services
Interventions: Drug: Lapatinib; Drug: Trastuzumab
Sponsors: City of Hope Medical Center; City of Hope Medical Center; GlaxoSmithKline; Genentech
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: secoisolariciresinol
Sponsors: University of Kansas; Carol Fabian, MD; Lignan Research, Inc.
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Drug: Eribulin Mesylate
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified March 2012 - Conditions: Epidermolysis Bullosa Dystrophica; Epidermolysis Bullosa
Intervention: Genetic: LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)
Sponsors: Stanford University; Stanford University; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified January 2012 - Condition: Human Papillomavirus Infection
Intervention:
Sponsors: Sanford Health; Sanford Health
Recruiting - verified September 2011 - Condition: Breast Cancer Screening
Interventions: Other: MI2 intervention arm; Other: Control
Sponsors: University of Kansas; University of Kansas
Recruiting - verified May 2012 - Condition: Melanoma
Interventions: Biological: MELITAC 12.1; Drug: Imiquimod
Sponsors: University of Virginia; University of Virginia
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Radiation: Hypofractionated Whole Breast Irradiation; Radiation: Conventionally Fractionated Whole Breast Irradiation
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011 - Conditions: HIV; HIV Lipodystrophy
Interventions: Drug: tesamorelin; Drug: placebo
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified April 2012 - Condition: Vitiligo
Interventions: Device: Dermabrasion-Micrografting; Procedure: Dermabrasion
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Momelan Technologies
Recruiting - verified May 2012 - Condition: Radiodermatitis
Intervention: Drug: Norepinephrine
Sponsors: ProCertus BioPharm, Inc; ProCertus BioPharm, Inc; University of Wisconsin, Madison
Recruiting - verified January 2012 - Condition: Breast Cancer
Intervention: Procedure: tumor biopsy and blood draw
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Drug: Dovitinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Recruiting - verified January 2012 - Condition: Dermatitis
Interventions: Biological: REGN668; Biological: REGN668; Biological: REGN668
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi-Aventis
Recruiting - verified February 2012 - Conditions: High-grade Dysplasia in Barrett Esophagus; Non Small Cell Lung Cancer; Esophageal Cancer
Interventions: Drug: Solar Protection Formula SPF® 60; Procedure: Photobiological testing; Procedure: Blood collection
Sponsors: Pinnacle Biologics Inc.; Pinnacle Biologics Inc.
Not yet recruiting - verified May 2012 - Condition: Psoriatic Arthritis
Interventions: Drug: Apremilast; Drug: • Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified June 2011 - Conditions: Lupus Erythematosus, Systemic; Systemic Vasculitis; Isolated Angiitis of Central Nervous System; Lung Disease With Systemic Sclerosis; Lung Disease Interstitial Diffuse
Interventions: Drug: depot leuprolide acetate 3.75 mg; Drug: Placebo
Sponsors: University of Michigan; Joseph Mccune; National Institutes of Health (NIH)
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Device: Diffuse Optical Spectroscopy Imaging
Sponsors: University of California, Irvine; Montana Compton; American College of Radiology Imaging Network; Massachusetts General Hospital; University of Pennsylvania; Dartmouth-Hitchcock Medical Center; Brown University; University of San Francisco
Recruiting - verified October 2011 - Condition: Breast
Intervention: Procedure: Delayed Breast Reconstruction
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Conditions: Breast Neoplasms; Breast Cancer; Breast Tumors; Cancer of Breast; Cancer of the Breast; Human Mammary Carcinoma; Neoplasms, Breast
Interventions: Procedure: Remove tumor only; Procedure: Removal of tumor and tissue
Sponsors: Emory University; Emory University
Recruiting - verified March 2012 - Condition: Breast Neoplasms
Intervention: Drug: GRN163L in combination with trastuzumab
Sponsors: Indiana University; Indiana University; Breast Cancer Research Foundation; Geron Corporation
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: carboplatin; Drug: veliparib; Other: 3'-deoxy-3'-[18F]fluorothymidine; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Arthur G. James Cancer Hospital & Richard J. Solove Research Institute; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: GDC-0980; Drug: paclitaxel
Sponsors: Genentech; Genentech
Recruiting - verified May 2012 - Condition: Breast Neoplasms
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011 - Conditions: Anal Cancer; Breast Cancer; Esophageal Cancer; Gastric Cancer; Head and Neck Cancer; Lung Cancer; Nonneoplastic Condition; Ovarian Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: vorinostat; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention: Device: Positron Emission Mammography (PEM) and Magnetic Resonance Imaging (MRI)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012 - Conditions: Stevens-Johnson Syndrome; Corneal Blindness
Intervention: Drug: Infliximab
Sponsors: Massachusetts Eye and Ear Infirmary; Massachusetts Eye and Ear Infirmary; Massachusetts Eye Research and Surgery Institution
Recruiting - verified May 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: BKM120; Drug: BEZ235; Drug: Letrozole; Drug: BKM120
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center
Recruiting - verified July 2011 - Condition: Breast Cancer
Intervention: Drug: Lovaza™
Sponsors: University of Kansas; Carol Fabian, MD
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Drug: Lovaza™
Sponsors: University of Kansas; Carol Fabian, MD; GlaxoSmithKline
Recruiting - verified February 2012 - Condition: Radiation-induced Dermatitis
Intervention: Drug: Curcumin
Sponsors: University of Rochester; University of Rochester; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Breast Cancer
Intervention: Radiation: Accelerated Partial Breast Irradiation (APBI)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Procedure: palliative surgery; Procedure: therapeutic conventional surgery; Radiation: palliative radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Atopic Dermatitis; Vitamin D Deficiency; Asthma
Intervention:
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; Children's Hospital and Health System Foundation, Wisconsin
Recruiting - verified July 2011 - Condition: Breast Cancer
Interventions: Drug: carboplatin; Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Drug: paclitaxel; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Arthur G. James Cancer Hospital & Richard J. Solove Research Institute; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Conditions: Mixed Muellerian Cancer; Cervical Cancer; Ovarian Cancer; Breast Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Endometrial Cancer; Carcinosarcoma
Interventions: Drug: Carboplatin; Drug: Olaparib; Drug: Treatment Effect
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011 - Conditions: Skin Cancer; Metastatic Melanoma
Interventions: Drug: Fludarabine; Drug: Cyclophosphamide; Other: Gene Transfer
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Breast Cancer
Interventions: Biological: Ramucirumab DP; Biological: IMC-18F1; Drug: Capecitabine
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified May 2012 - Condition: Advanced HER2-positive Breast Cancer
Intervention: Drug: AUY922 + Trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: entinostat; Drug: tamoxifen citrate; Genetic: reverse transcriptase-polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified January 2011 - Condition: Psoriasis
Intervention: Drug: Acitretin 17.5 mg/day
Sponsors: Frankel, Amylynne, M.D.; Frankel, Amylynne, M.D.; Stiefel, a GSK Company
Recruiting - verified June 2011 - Conditions: Churg-Strauss Syndrome; Giant Cell Arteritis; Granulomatosis With Polyangiitis (Wegener's); Microscopic Polyangiitis; Polyarteritis Nodosa; Takayasu's Arteritis
Intervention:
Sponsors: Boston University; Boston University; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Office of Rare Diseases (ORD); Rare Diseases Clinical Research Network
Recruiting - verified February 2012 - Conditions: Chemotherapeutic Agent Toxicity; Pain; Peripheral Neuropathy; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Therapy-related Toxicity
Interventions: Procedure: cryotherapy; Other: questionnaire administration; Procedure: quality-of-life assessment; Procedure: management of therapy complications; Procedure: assessment of therapy complications
Sponsors: Northwestern University; Northwestern University; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: Eniluracil; Drug: 5-Fluorouracil; Drug: Leucovorin; Drug: Capecitabine
Sponsors: Adherex Technologies, Inc.; Adherex Technologies, Inc.
Recruiting - verified August 2011 - Condition: Breast Cancer
Intervention:
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified January 2012 - Conditions: Paravertebral Catheter Insertion; Mastectomy; Breast Cancer
Interventions: Procedure: Placebo (normal saline) Continuous Infusion; Procedure: Ropivicaine 0.4% Continuous Infusion
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified March 2012 - Condition: Actinic Keratosis
Interventions: Drug: Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm; Drug: Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
Sponsors: Frankel, Amylynne, M.D.; Frankel, Amylynne, M.D.; Graceway Pharmaceuticals, LLC
Recruiting - verified June 2011 - Condition: Foot Ulcers, Diabetic
Intervention: Device: PriMatrix
Sponsors: TEI Biosciences Inc.; TEI Biosciences Inc.; Mayo Clinic; California School of Podiatric Medicine; New York College of Podiatric Medicine; Temple University
Recruiting - verified June 2011 - Condition: Foot Ulcer, Diabetic
Intervention: Device: PriMatrix
Sponsors: TEI Biosciences Inc.; TEI Biosciences Inc.; Beth Israel Deaconess Medical Center
Recruiting - verified June 2011 - Condition: Herpes Labialis
Interventions: Drug: onabotulinumtoxinA; Other: Bacteriostatic normal saline
Sponsors: DeNova Research; DeNova Research; Allergan
Recruiting - verified June 2011 - Condition: Breast Cancer
Interventions: Drug: BMS-754807; Drug: letrozole
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Mayo Clinic
Recruiting - verified December 2011 - Condition: Breast Cancer
Interventions: Dietary Supplement: vitamin D; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention: Behavioral: Behavioral activation/problem-solving (BA/PS)
Sponsors: Dartmouth-Hitchcock Medical Center; Dartmouth-Hitchcock Medical Center; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Conditions: Primary Immune Deficiency; Candida; Autoimmune Polyendocrinopathy Candidiasis Ectodermal; Chronic Mucocutaneous Candidiasis (CMC); Fungal Infection
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2011 - Condition: Cutaneous Lupus Erythematosus
Intervention: Drug: CC-11050
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified February 2012 - Condition: Breast Neoplasm
Intervention: Drug: Tesetaxel
Sponsors: Genta Incorporated; Genta Incorporated
Recruiting - verified November 2011 - Condition: Post-Mastectomy Breast Cancer Reconstruction
Interventions: Device: Contour Profile Tissue Expander; Device: Standard Round Tissue Expander
Sponsors: Northwestern University; Northwestern University; Mentor Worldwide, LLC
Recruiting - verified July 2011 - Condition: Breast Cancer
Interventions: Drug: Ridaforolimus + Dalotuzumab; Drug: Ridaforolimus; Drug: Dalotuzumab
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Conditions: Neoplasms, Breast; WT1-positive Primary Invasive Breast Cancer
Interventions: Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A; Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: systemic chemotherapy; Other: laser spectroscopy; Procedure: breast imaging study; Procedure: magnetic resonance imaging; Procedure: mammography; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery; Procedure: ultrasound imaging
Sponsors: National Cancer Institute (NCI); American College of Radiology Imaging Network; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in Situ; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer
Interventions: Dietary Supplement: soy isoflavones; Other: placebo; Other: questionnaire administration; Procedure: magnetic resonance imaging; Procedure: biopsy; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: mammography
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI); California Breast Cancer Research Program
Recruiting - verified May 2012 - Conditions: Mastectomy; Breast Neoplasms
Interventions: Procedure: ultrasound; Procedure: predetermined distance
Sponsors: Ochsner Health System; Ochsner Health System
Recruiting - verified October 2011 - Conditions: Breast Cancer; Breast Cancer Surgery
Intervention: Device: Positron Emission Mammography (PEM)
Sponsors: Swedish Medical Center; Swedish Medical Center
Recruiting - verified May 2012 - Conditions: Breast Cancer; Breast Reconstruction; Nipple Reconstruction
Intervention: Device: Nipple reconstruction
Sponsors: Cook; Cook
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: Anastrozole; Drug: ADZ0530; Drug: Placebo; Procedure: Pharmacokinetic studies; Procedure: Definitive Surgery; Procedure: Core Biopsy; Genetic: Tumor Tissue Collection for Genetic and Molecular Studies
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center; Doris Duke Charitable Foundation
Recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine; Drug: Placebo / Capecitabine
Sponsors: Bayer; Bayer; Onyx Therapeutics, Inc.
Recruiting - verified April 2012 - Conditions: Cryopyrin-associated Periodic Syndromes (CAPS); Familial Cold Autoinflam Syn (FCAS); Muckle-wells Syn (MWS); Neonatal Onset Multisystem Inflam Disease (NOMID)
Intervention:
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Melanoma; NY-ESO-1-positive; Progressive Metastatic Cutaneous Melanoma; Unresectable
Intervention: Biological: GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Radiation: Radiopharmaceutical Administration [18F]-FDG; Radiation: Radiopharmaceutical: [18F]-FLT
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center
Recruiting - verified November 2011 - Conditions: Anal Cancer; Nonneoplastic Condition; Penile Cancer; Precancerous Condition
Interventions: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Breast Cancer; Ductal Carcinoma
Interventions: Procedure: Nipple Area Complex-Sparing Mastectomy; Radiation: Nipple Area Complex Irradiation; Procedure: Breast Reconstruction; Procedure: Axillary Dissection or Sentinel Node Biopsy (SNB); Drug: Chemotherapy
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified October 2011 - Conditions: HER2-positive Breast Cancer; Male Breast Cancer; Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine; Drug: cyclophosphamide; Biological: ex vivo-expanded HER2-specific T cells; Other: laboratory biomarker analysis; Other: flow cytometry; Other: immunoenzyme technique
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified May 2012 - Condition: Vitiligo Vulgaris
Intervention:
Sponsors: St. Luke's-Roosevelt Hospital Center; St. Luke's-Roosevelt Hospital Center; Beth Israel Medical Center
Recruiting - verified July 2011 - Condition: Breast Cancer
Intervention: Radiation: multiple beams utilizing either intensity-modulated or 3D-conformal techniques
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012 - Condition: Actinic Keratosis
Interventions: Drug: Imiquimod/photodynamic therapy; Drug: Imiquimod only
Sponsors: Tennessee Clinical Research Center; Tennessee Clinical Research Center; Graceway Pharmaceuticals, LLC
Recruiting - verified July 2011 - Condition: Breast Cancer
Interventions: Other: Yoga Program; Other: Stretching + Relaxation Program; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011 - Condition: Metastatic Breast Cancer
Interventions: Drug: Abraxane; Drug: Carboplatin
Sponsors: Duke University; Duke University; Celgene Corporation
Recruiting - verified September 2011 - Condition: Venous Leg Ulcers
Interventions: Drug: Nexagon® 1.0 mg/mL; Drug: Nexagon® 3.0 mg/mL; Drug: Nexagon® Vehicle; Device: Compression dressings
Sponsors: CoDa Therapeutics Inc.; CoDa Therapeutics Inc.
Recruiting - verified November 2011 - Conditions: Breast Cancer; Ovarian Insufficiency; Ovarian Failure
Intervention:
Sponsors: University of California, San Diego; University of California, San Diego; University of Pennsylvania; American Cancer Society; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified August 2011 - Condition: Advanced or Metastatic Breast Cancer
Intervention: Drug: KW-2450 in combination with lapatinib and letrozole
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Pharma, Inc.
Recruiting - verified February 2012 - Condition: Skin Cancer
Intervention: Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; OSI Pharmaceuticals
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: Tamoxifen Citrate; Drug: Placebo
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI); St. Jude Children's Research Hospital; University Health Network, Toronto; Emory University; University of Michigan
Recruiting - verified February 2012 - Conditions: Non-Small Cell Lung Neoplasms; Prostate Neoplasms; Bladder Neoplasms; Ovarian Neoplasms; Breast Neoplasms
Intervention: Drug: MGAH22
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Breast Cancer
Intervention: Drug: Sorafenib
Sponsors: Emory University; Emory University; Onyx Pharmaceuticals; Bayer
Recruiting - verified April 2012 - Conditions: Breast Cancer; Breast Tumors; Breast Neoplasms
Intervention: Drug: Decitabine, LHB589, Tamoxifen
Sponsors: Emory University; Emory University; Novartis; Eisai Inc.
Recruiting - verified May 2012 - Conditions: Ductal Carcinoma in Situ; Estrogen Receptor-positive Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: letrozole; Drug: zoledronic acid; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Other: mass spectrometry; Procedure: bone scan; Procedure: quality-of-life assessment; Other: questionnaire administration; Other: pharmacogenomic studies; Other: high performance liquid chromatography
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified January 2012 - Condition: Skin Cancer
Interventions: Behavioral: Part 1: Interview + Questionnaires; Behavioral: Part 2: Multiple Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Conditions: Human Papillomavirus Infection; Cervical Neoplasia
Interventions: Procedure: Gynaecological follow-up; Biological: Cervarix™; Biological: Placebo control
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Hereditary Angioedema
Interventions: Drug: rhC1INH; Drug: Placebo (Saline)
Sponsors: Pharming Technologies B.V.; Pharming Technologies B.V.
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Device: Focused Microwave Thermotherapy; Drug: Chemotherapy (control)
Sponsors: Medifocus, Inc.; Medifocus, Inc.
Recruiting - verified August 2011 - Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Behavioral: High-Intensity Aerobic Training; Behavioral: Moderate-Intensity Aerobic Training; Behavioral: Progressive Stretching
Sponsors: Duke University; Duke University
Recruiting - verified July 2011 - Condition: Breast Cancer
Interventions: Radiation: accelerated partial breast irradiation - 3D-conformal planning; Radiation: accelerated partial breast irradiation - IMRT planning
Sponsors: Rocky Mountain Cancer Centers; Rocky Mountain Cancer Centers
Recruiting - verified March 2011 - Condition: Breast Cancer
Intervention: Behavioral: Cogmed Working Memory Training Program
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; MARTELL FOUNDATION
Recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: MetMAb; Drug: paclitaxel; Drug: placebo
Sponsors: Genentech; Genentech; Hoffmann-La Roche
Recruiting - verified March 2012 - Conditions: Multiple Myeloma; Diffuse Large B-Cell Lymphoma; Glioblastoma Multiforme; Hepatocellular Carcinoma; Non-Small Cell Lung Cancer; Gastrointestinal Neuroendocrine Tumors of Non-Pancreatic Origin; Hormone Receptor-Positive Breast Cancer
Intervention: Drug: CC-223
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012 - Condition: Psoriasis
Intervention:
Sponsors: Rockefeller University; Rockefeller University; Weill Medical College of Cornell University
Recruiting - verified May 2012 - Condition: Subjects With Breast Cancer
Interventions: Other: Blood, Echocardiography, and Questionnaire Timepoints for Anthracycline abd Trastuzumab; Other: Blood, Echocardiography and Questionnaire for Trastuzumab; Other: Blood, Echocardiography and Questionnaire for Anthracycline Regimen
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012 - Conditions: Estrogen Receptor Negative (ER-Negative) Breast Cancer; Progesterone Receptor Negative (PR-Negative) Breast Cancer; Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer; Brain Metastases
Intervention: Drug: INIPARIB + irinotecan
Sponsors: Sanofi-Aventis; Sanofi-Aventis; UNC Lineberger Comprehensive Cancer Center
Recruiting - verified October 2011 - Conditions: Atopic Dermatitis; Netheron's Syndrome; Piebaldism; Hyper IgE Syndrome; Ichthyosis; Anaphylaxis; Severe Allergy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012 - Condition: Early Stage Breast Cancer
Intervention:
Sponsors: Summa Health System; Summa Health System
Recruiting - verified April 2012 - Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Cutaneous Lupus; Discoid Lupus; Lupus; Systemic Lupus Erythematosus
Interventions: Drug: AMG811; Drug: AMG811 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified March 2012 - Conditions: Taxane Induced Neuropathy; Breast Cancer
Interventions: Other: Electro-acupuncture; Other: Sham acupuncture
Sponsors: Columbia University; Columbia University; Breast Cancer Research Foundation
Recruiting - verified October 2011 - Conditions: Pleural Metastases; Breast Cancer; Colon Cancer; Ovarian Cancer; Uterine Cancer; Renal Cell Cancer; Thymic Cancer
Intervention: Procedure: Surgical debulking and Intrathoracic Hyperthermic Chemotherapy
Sponsors: St. Luke's-Roosevelt Hospital Center; St. Luke's-Roosevelt Hospital Center
Recruiting - verified September 2011 - Condition: Breast Cancer
Intervention: Drug: paclitaxel
Sponsors: University of Kansas; University of Kansas; Novartis
Recruiting - verified October 2011 - Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast CancerCondition: Breast Neoplasms
Intervention: Drug: Platinum based chemotherapy, radiation, surgery
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011 - Conditions: High Mammographic Density; Breast Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Other: standardized regimen of exercises, including a warm-up period, ROM arm exercises, and strength training exercises.
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified November 2011 - Conditions: Sleep Initiation and Maintenance Disorders; Breast Cancer
Intervention: Procedure: acupuncture
Sponsors: Stanford University; Stanford University; National Institutes of Health (NIH); National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified January 2012 - Condition: Breast Cancer
Intervention: Device: Magnetic resonance imaging
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Neoplasms, Breast
Interventions: Drug: lapatinib; Drug: trastuzumab; Drug: Aromatase inhibitor; Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Early Stage Breast Cancer (Stage 0-III)
Intervention: Other: Exercise Regimen
Sponsors: Nevada Cancer Institute; Nevada Cancer Institute; Vons
Recruiting - verified July 2011 - Condition: Breast Cancer
Intervention: Behavioral: Comprehensive Health Enhancement Support System (CHESS.)
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Conditions: Atopic Dermatitis; Eczema
Intervention: Drug: Cyclosporine A
Sponsors: Rockefeller University; Rockefeller University
Recruiting - verified February 2012 - Condition: Her2 Negative Breast Cancer Patients
Interventions: Drug: MM-121 (SAR256212) and Exemestane; Drug: Placebo and Exemestane
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified May 2012 - Condition: Psoriasis
Interventions: Behavioral: Mindfulness-Based Stress Reduction; Behavioral: Living Well
Sponsors: University of Rochester; University of Rochester; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified December 2011 - Condition: Major Depression
Interventions: Behavioral: Interpersonal Psychotherapy; Behavioral: Problem-Solving Therapy; Behavioral: Brief Supportive Psychotherapy
Sponsors: New York State Psychiatric Institute; New York State Psychiatric Institute
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Device: Radiofrequency Ablation
Sponsors: University of Arkansas; University of Arkansas; Angiodynamics, Inc.
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Drug: goserelin acetate
Sponsors: National Cancer Institute (NCI); H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Conditions: Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: vorinostat; Other: laboratory biomarker analysis; Procedure: biopsy; Radiation: F-18 16 alpha-fluoroestradiol; Procedure: positron emission tomography; Drug: anastrozole; Drug: letrozole; Drug: exemestane; Genetic: gene expression analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Breast Cancer
Intervention: Device: Intraoperative Radiotherapy
Sponsors: Hoag Memorial Hospital Presbyterian; Hoag Memorial Hospital Presbyterian
Recruiting - verified April 2012 - Condition: Eczema
Interventions: Other: Group eczema education session; Other: Control group
Sponsors: Oregon Health and Science University; Oregon Health and Science University
Recruiting - verified May 2010 - Conditions: Breast Cancer; Gastric Cancer; Bladder Cancer; Ovarian Cancer; Non-small Cell Lung Cancer
Intervention: Biological: MGAH22
Sponsors: MacroGenics; MacroGenics; Green Cross Corporation; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Biological: HER2Bi-armed activated T cells; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel; Other: laboratory biomarker analysis; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Diabetic Foot Ulcers
Interventions: Drug: Santyl; Other: White Petrolatum
Sponsors: Healthpoint; Healthpoint
Recruiting - verified December 2011 - Condition: Leishmaniasis, Cutaneous
Intervention: Drug: WR 279,396
Sponsors: U.S. Army Medical Research and Materiel Command; U.S. Army Medical Research and Materiel Command; Walter Reed National Military Medical Center; Walter Reed Army Institute of Research (WRAIR)
Recruiting - verified February 2012 - Conditions: Breast Cancer; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: questionnaire administration; Procedure: evaluation of cancer risk factors; Procedure: quality-of-life assessment; Procedure: study of high risk factors
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Psoriasis; Obesity
Intervention: Behavioral: Weight Loss
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; National Institutes of Health (NIH)
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Genetic: gene expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: laboratory biomarker analysis; Other: medical chart review; Other: questionnaire administration
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Behavioral: survey web-based or telephone interview; Behavioral: survey web-based or telephone interview
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; The City College of New York; New York City Health and Hospitals Corporation; Lincoln Medical and Mental Health Center; New York Hospital Queens; Ralph Lauren Center for Cancer Care and Prevention
Recruiting - verified May 2012 - Conditions: Breast Cancer; Quality of Life; Physical Activity
Intervention: Behavioral: Physical activity counseling
Sponsors: East Carolina University; East Carolina University
Recruiting - verified June 2011 - Conditions: Anakinra; Kineret; Atopic Dermatitis; Eczema; Allergic Disease
Intervention: Drug: Anakinra
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2011 - Condition: Breast Cancer
Intervention:
Sponsors: Aurora Health Care; David Rohde
Recruiting - verified January 2012 - Condition: Breast Cancer
Intervention: Radiation: Multi-Beam Intensity-Modulated Radiation Therapy
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012 - Condition: Breast Cancer
Intervention: Drug: RAD001
Sponsors: New York University School of Medicine; New York University School of Medicine; Novartis Pharmaceuticals
Recruiting - verified December 2011 - Conditions: Breast Cancer; Rectal Cancer; Colon Cancer; Obesity
Intervention: Dietary Supplement: dietary intervention
Sponsors: Rockefeller University; Rockefeller University
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: tamoxifen citrate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Psoriatic Arthritis
Interventions: Drug: Methotrexate; Drug: Anti-TNF
Sponsors: University of Rochester; University of Rochester; National Psoriasis Foundation
Recruiting - verified October 2011 - Condition: Rosacea
Interventions: Drug: vehicle gel; Drug: Atralin gel
Sponsors: University of Michigan; University of Michigan; Valeant Pharmaceuticals International, Inc.
Recruiting - verified October 2011 - Condition: Breast Neoplasms
Interventions: Drug: BIBW 2992; Drug: trastuzumab; Drug: vinorelbine; Drug: vinorelbine
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Metastatic Breast Cancer; Trastuzumab; BKM120; HER2+
Intervention: Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Hyperpigmentation
Interventions: Other: Nu Skin Product; Other: Cosmetic instrument; Drug: Tretinoin cream 0.05; Other: CeraVe moisturizer
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified July 2011 - Conditions: Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Interventions: Drug: cediranib; Drug: olaparib
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; University of Chicago; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: pertuzumab; Drug: pertuzumab-placebo; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: paclitaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Genentech
Recruiting - verified March 2012 - Conditions: Breast Cancer; Fatigue
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified April 2012 - Conditions: Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Interventions: Other: questionnaire administration; Behavioral: exercise intervention; Procedure: quality-of-life assessment; Other: survey administration; Procedure: management of therapy complications; Procedure: psychosocial assessment and care
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University
Recruiting - verified April 2012 - Conditions: Breast Cancer; Overweight; Obesity
Interventions: Behavioral: Intensive Group; Behavioral: Less Intensive Group
Sponsors: University of California, San Diego; University of California, San Diego; Washington University School of Medicine; University of Colorado, Denver; University of Alabama at Birmingham
Recruiting - verified March 2010 - Conditions: Behcet's Disease; Uveitis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Eye Institute (NEI)
Recruiting - verified February 2012 - Conditions: Impetigo; Folliculitis; Secondarily Infected Eczema; Minor Soft Tissue Infections
Intervention: Drug: Retapamulin (Altabax)
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; GlaxoSmithKline
Recruiting - verified February 2012 - Conditions: Head and Neck Cancer; Breast Cancer; Head and Neck Cancers
Intervention: Procedure: FNA Biopsy
Sponsors: Stanford University; Stanford University
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention: Drug: Temsirolimus plus Neratinib
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Comprehensive Cancer Network; Wyeth Pharmaceuticals, Inc., a Pfizer Company
Recruiting - verified May 2012 - Conditions: Breast Cancer; Lymphoma
Intervention: Behavioral: questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified November 2011 - Conditions: Staphylococcus Aureus; Community-associated MRSA Infections; Staphylococcal Skin Infections
Interventions: Drug: Chlorhexidine gluconate; Other: Standardized training and education
Sponsors: Uniformed Services University of the Health Sciences; Uniformed Services University of the Health Sciences; Centers for Disease Control and Prevention
Recruiting - verified July 2011 - Conditions: Skin Cancers; Carcinoma, Basal Cell; Skin Cancer; Basal Cell Carcinoma
Intervention: Drug: Itraconazole
Sponsors: Stanford University; Stanford University
Recruiting - verified December 2011 - Condition: Breast Cancer
Intervention:
Sponsors: Duke University; Duke University; National Institutes of Health (NIH); National Cancer Institute (NCI)
Recruiting - verified June 2011 - Condition: Dermatomyositis
Intervention: Drug: Apremilast
Sponsors: Stanford University; Stanford University
Recruiting - verified July 2011 - Condition: Breast Cancer
Interventions: Drug: letrozole; Drug: panobinostat; Genetic: RNA analysis; Genetic: microarray analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Includes: Hereditary Angioedema
Intervention: Biological: Berinert® (C1 Esterase Inhibitor)
Sponsors: CSL Behring; CSL Behring; Chiltern International Inc.
Recruiting - verified May 2012 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Breast Cancer
Interventions: Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Cyclosporine; Biological: Natural killer cells; Drug: IL-2; Drug: Methylprednisolone; Drug: Methylprednisolone; Drug: Interleukin-2
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012 - Conditions: Estrogen Receptor-negative Breast Cancer; Hereditary Breast/Ovarian Cancer - BRCA1; Hereditary Breast/Ovarian Cancer - BRCA2; Male Breast Cancer; Progesterone Receptor-negative Breast Cancer; Recurrent Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer
Interventions: Other: immunohistochemistry staining method; Genetic: gene expression analysis; Drug: veliparib; Drug: cisplatin; Drug: vinorelbine tartrate; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Drug: metformin hydrochloride; Other: placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Metastatic Breast Cancer
Intervention: Drug: Indibulin
Sponsors: ZIOPHARM; ZIOPHARM; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012 - Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer
Interventions: Dietary Supplement: cholecalciferol; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: HER2 Amplified Breast Cancer; Metastatic or Advanced Breast Cancer
Intervention: Drug: MM-111 and Herceptin
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: Cetuximab; Drug: Ixabepilone
Sponsors: The Methodist Hospital System; The Methodist Hospital System; Bristol-Myers Squibb
Recruiting - verified June 2011 - Condition: Hereditary Angioedema
Intervention: Biological: Cinryze
Sponsors: ViroPharma; ViroPharma
Recruiting - verified April 2011 - Conditions: Breast Cancer; Stage IV Breast Cancer
Interventions: Procedure: positron emission tomography; Radiation: copper Cu 64-DOTA-trastuzumab; Procedure: Biopsy; Other: Immunohistochemistry staining method; Other: laboratory biomarker analysis; Genetic: mutation analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified May 2012 - Condition: Moderate to Severe Palmar Plantar Psoriasis
Intervention: Drug: Ustekinumab
Sponsors: Tufts Medical Center; Tufts Medical Center; Centocor, Inc.
Recruiting - verified July 2011 - Conditions: Ovarian Carcinoma; Fallopian Tube Cancer; Peritoneal Cancer; Breast Carcinoma
Interventions: Drug: MLN8237 + Paclitaxel; Drug: MLN8237+Paclitaxel vs. Paclitaxel alone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified December 2011 - Condition: Stages II-III Breast Cancer
Interventions: Drug: Nanoparticle Albumin Bound Paclitaxel; Drug: doxorubicin; Drug: cyclophosphamide
Sponsors: University of South Alabama; University of South Alabama; Celgene Corporation
Recruiting - verified August 2011 - Conditions: Breast Cancer; Lung Cancer; Renal Cancer; Adrenal Cancer
Intervention: Drug: F-18 Paclitaxel (FPAC)
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Not yet recruiting - verified September 2011 - Condition: Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Interventions: Biological: Rituximab; Other: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2011 - Condition: Scalp Psoriasis
Intervention: Drug: LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)
Sponsors: LEO Pharma; LEO Pharma
Recruiting - verified March 2011 - Conditions: Breast Cancer; Gynecologic Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified December 2011 - Conditions: Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: vorinostat; Drug: ixabepilone; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified March 2012 - Condition: Female Breast Cancer
Intervention: Drug: Estradiol
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Other: circulating tumor cell analysis; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal accelerated partial breast irradiation
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Breast Cancer
Interventions: Drug: XL147 (SAR245408); Drug: XL765 (SAR245409); Drug: letrozole (Femara)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Condition: Arthritis, Psoriatic
Interventions: Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: placebo; Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: ustekinumab
Sponsors: Centocor, Inc.; Centocor, Inc.
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention: Drug: letrozole
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI); University of Arizona
Recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Drug: Cisplatin; Drug: Rucaparib; Drug: Cisplatin
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Clovis Oncology, Inc.
Recruiting - verified March 2012 - Condition: Metastatic Breast Cancer
Intervention: Drug: (will be assigned based on molecular profile and RPMA)
Sponsors: TGen Drug Development Services; TGen Drug Development Services; SideOut Foundation
Recruiting - verified January 2012 - Condition: Breast Cancer
Intervention: Procedure: Low-Level Laser Therapy
Sponsors: Northwestern University; Northwestern University; Robert H. Lurie Cancer Center
Not yet recruiting - verified October 2011 - Conditions: Wegener's Granulomatosis; Microscopic Polyangiitis; Churg Strauss Syndrome; Polyarteritis Nodosa; Giant Cell Arteritis; Takayasu Arteritis
Intervention:
Sponsors: University of Oxford; University of Oxford; American College of Rheumatology; The European League Against Rheumatism (EULAR); The Vasculitis foundation
Recruiting - verified January 2012 - Condition: Critical Limb Ischemia
Interventions: Genetic: VM202; Genetic: VM202; Other: Normal Saline
Sponsors: ViroMed Co., Ltd.; ViroMed Co., Ltd.; VM Biopharma
Recruiting - verified February 2012 - Conditions: Pain; Breast Cancer; Lung Cancer
Interventions: Drug: Gabapentin; Drug: Placebo
Sponsors: Stanford University; Stanford University
Recruiting - verified September 2011 - Conditions: Nephrogenic Fibrosing Dermopathy; Nephrogenic Systemic Fibrosis
Intervention: Procedure: Plasmapheresis
Sponsors: Loma Linda University; Loma Linda University
Recruiting - verified June 2011 - Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: Denosumab
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified May 2012 - Conditions: Pathologic Skin Picking; Neurotic Excoriation; Psychogenic Excoriation; Dermatillomania
Interventions: Drug: N-Acetyl Cysteine; Drug: Placebo
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified March 2012 - Condition: Foot Ulcer, Diabetic
Interventions: Device: Integra® Dermal Regeneration Template; Other: Conventional Wound Therapy
Sponsors: Integra LifeSciences Corporation; Integra LifeSciences Corporation
Recruiting - verified August 2011 - Condition: Hereditary Angioedema
Intervention: Drug: ecallantide
Sponsors: Dyax Corp.; Dyax Corp.
Recruiting - verified April 2012 - Conditions: Metastatic Non Small Cell Lung Cancer; Metastatic Breast Cancer
Interventions: Drug: Pazopanib; Drug: Vinorelbine
Sponsors: Northwestern University; Northwestern University; Robert H. Lurie Cancer Center
Recruiting - verified October 2011 - Condition: Skin Cancer
Intervention: Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; OSI Pharmaceuticals
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Drug: EF5; Procedure: Partial or Total Mastectomy
Sponsors: Duke University; Duke University; National Institutes of Health (NIH); National Cancer Institute (NCI)
Not yet recruiting - verified June 2011 - Conditions: Erythematotelangiectatic Rosacea; Papulopustular Rosacea
Intervention: Drug: Apremilast
Sponsors: Columbia University; Columbia University; Celgene Corporation
Recruiting - verified February 2012 - Conditions: Cardiovascular Complications; Recurrent Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: rosuvastatin; Other: placebo; Other: survey administration; Procedure: management of therapy complications
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Other: History and Physical Exam; Other: Grip Strength Measurement; Behavioral: Surveys; Other: Blood Collection; Procedure: Ultrasound of Hand/Wrist
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified February 2012 - Conditions: Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Procedure: acupuncture therapy; Drug: paclitaxel; Other: questionnaire administration; Procedure: management of therapy complications
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Procedure: PRO Onc Assay; Drug: Trastuzumab; Drug: Pertuzumab
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Prometheus Therapeutics and Diagnostics; Genentech
Recruiting - verified April 2012 - Conditions: Locally Advanced Breast Cancer; Metastatic (Stage IV) Breast Cancer; Stage III-IV Breast Cancer or Inflammatory
Intervention:
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI); Palo Alto Research Center
Recruiting - verified March 2012 - Condition: Systemic Scleroderma
Interventions: Drug: fludarabine phosphate; Radiation: total-body irradiation; Drug: tacrolimus; Drug: mycophenolate mofetil; Biological: rituximab; Drug: cyclophosphamide; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified May 2012 - Conditions: Advanced Nonhematological Malignancies; Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Metastatic Breast Cancer; Head and Neck Squamous Cell Carcinoma; Gastroesophageal Adenocarcinoma
Intervention: Drug: MLN8237
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Device: Computed Tomography; Device: Computed Tomography
Sponsors: Koning Corporation; Koning Corporation; Elizabeth Wende Breast Care; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Biological: Ad.p53 DC vaccine; Drug: 1-methyl-D-tryptophan (1-MT)
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Breast Neoplasms; Breast Cancer; Breast Tumors
Interventions: Drug: Neratinib; Drug: ABT-888; Drug: Standard Therapy; Drug: AMG 386; Drug: AMG 479 (Ganitumab) plus Metformin
Sponsors: Foundation for the National Institutes of Health; Foundation for the National Institutes of Health
Recruiting - verified December 2011 - Condition: Angioedema
Intervention: Drug: ecallantide - Kallikrein inhibitor that blocks the production of bradykinin
Sponsors: Bernstein, Jonathan A., M.D.; Bernstein, Jonathan A., M.D.; Dyax Corp.
Recruiting - verified March 2012 - Condition: Epidermolysis Bullosa
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Anti-thymocyte globulin; Drug: Cyclosporine A; Drug: Mycophenolate mofetil; Procedure: Hematopoietic stem cell transplant; Procedure: Mesenchymal stem cell transplant; Radiation: Total body irradiation
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified May 2012 - Conditions: Breast Cancer; Breast Cancer Non-invasive Breast Cancer
Intervention: Procedure: MRI
Sponsors: Stanford University; Stanford University; National Institutes of Health (NIH)
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Panitumumab; Drug: Nab-paclitaxel; Drug: Carboplatin; Drug: 5-Fluorouracil; Drug: Epirubicin; Drug: Cyclophosphamide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation; Amgen
Recruiting - verified April 2012 - Condition: Metastatic Breast Cancer
Intervention: Drug: Amrubicin
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Celgene Corporation
Recruiting - verified July 2011 - Condition: Primary Breast Cancer
Intervention: Behavioral: Enhanced ICCS with KPNW web resources and the Comprehensive Health Enhancement Support System (CHESS.)
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Conditions: Adult Solid Tumor; Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Adult Central Nervous System Germ Cell Tumor; Adult Teratoma; Benign Teratoma; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Familial Testicular Germ Cell Tumor; HER2-negative Breast Cancer; HER2-positive Breast Cancer; Male Breast Cancer; Ovarian Immature Teratoma; Ovarian Mature Teratoma; Ovarian Monodermal and Highly Specialized Teratoma; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Extragonadal Germ Cell Tumor; Recurrent Extragonadal Non-seminomatous Germ Cell Tumor; Recurrent Extragonadal Seminoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Melanoma; Recurrent Ovarian Germ Cell Tumor; Recurrent Rectal Cancer; Stage III Extragonadal Non-seminomatous Germ Cell Tumor; Stage III Extragonadal Seminoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Ovarian Germ Cell Tumor; Stage IV Breast Cancer; Stage IV Colon Cancer; Stage IV Extragonadal Non-seminomatous Germ Cell Tumor; Stage IV Extragonadal Seminoma; Stage IV Melanoma; Stage IV Ovarian Germ Cell Tumor; Stage IV Rectal Cancer; Testicular Immature Teratoma; Testicular Mature Teratoma
Interventions: Drug: PD-0332991; Other: pharmacological study
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention:
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified March 2012 - Conditions: Carcinoma, Intraductal, Noninfiltrating; DCIS; Ductal Carcinoma In Situ
Interventions: Drug: Chloroquine Standard Dose (500mg/week); Drug: Chloroquine Low Dose (250mg/week); Procedure: Breast Biopsy
Sponsors: Inova Health Care Services; Inova Health Care Services; George Mason University; Department of Defense; U.S. Army Medical Research and Materiel Command
Recruiting - verified March 2012 - Conditions: Eyelash Hypotrichosis; Alopecia Areata
Interventions: Drug: bimatoprost ophthalmic solution 0.03%; Drug: Vehicle Sterile Solution
Sponsors: Allergan; Allergan
Recruiting - verified November 2011 - Conditions: Psoriasis; Cardiovascular Diseases; Dyslipidemia
Intervention:
Sponsors: George Washington University; George Washington University
Recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Biological: HER2Bi-armed activated T cells; Drug: Cyclophosphamide; Other: Laboratory biomarker analysis
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Breast Cancer
Interventions: Radiation: accelerated partial breast irradiation; Radiation: intracavitary balloon brachytherapy
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; SenoRx, Inc.
Recruiting - verified December 2011 - Condition: Refractory Head and Neck Cancer, Squamous Cell Carcinoma of the Skin, Carcinoma of the Breast, and Malignant Melanoma
Intervention: Drug: HF10
Sponsors: Takara Bio Inc.; Takara Bio Inc.
Recruiting - verified October 2011 - Conditions: Breast Cancer; Colorectal Cancer; Myeloma; Chemotherapy-induced Peripheral Neuropathy
Interventions: Behavioral: Questionnaire; Behavioral: Sensory Tests; Behavioral: Interview
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: Chronic Stable Plaque Psoriasis
Interventions: Drug: Clobex Spray; Drug: Vectical Ointment; Procedure: Excimer Laser
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified January 2012 - Conditions: Breast Cancer; Recurrent Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Procedure: acupuncture therapy; Procedure: sham intervention
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention: Device: Positron Emission Mammography
Sponsors: University of Chicago; University of Chicago
Recruiting - verified June 2011 - Conditions: Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Biological: panitumumab; Drug: paclitaxel; Drug: carboplatin; Procedure: laboratory biomarker analysis; Procedure: immunohistochemistry staining method
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University
Recruiting - verified April 2012 - Conditions: Breast Cancer; Cardiac Toxicity
Interventions: Drug: carvedilol phosphate extended-release capsule; Drug: lisinopril; Other: placebo
Sponsors: National Cancer Institute (NCI); University of South Florida; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Drug: VPA FEC100
Sponsors: University of California, San Francisco; University of California, San Francisco; H. Lee Moffitt Cancer Center and Research Institute
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: ritonavir; Procedure: therapeutic conventional surgery
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota; Susan G. Komen Breast Cancer Foundation
Recruiting - verified January 2012 - Condition: Breast Cancer
Intervention: Other: ChemoFX Assay
Sponsors: Precision Therapeutics; Precision Therapeutics; Department of Defense
Recruiting - verified December 2011 - Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Trastuzumab; Drug: Neratinib; Drug: Trastuzumab (post surgery); Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Wyeth Pharmaceuticals, Inc., a Pfizer Company
Recruiting - verified February 2012 - Conditions: HER2/Neu Over-expressing Locally Advanced Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: everolimus, vinorelbine, trastuzumab; Drug: Placebo + vinorelbine + trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Cancer
Intervention: Drug: Valproic Acid
Sponsors: University of Utah; University of Utah
Recruiting - verified January 2012 - Condition: Hot Flashes
Intervention: Drug: Gabapentin
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012 - Conditions: Solid Tumors; Mucoepidermal Carcinoma (MEC) of the Salivary Gland; Pigmented Villo-nodular Synovitis (PVNS); Gastrointestinal Stromal Tumors (GIST); Anaplastic Thyroid Carcinoma (ATC); Solid Tumors With Documented Malignant Pleural or Peritoneal Effusions; Malignant Peripheral Nerve Sheath Tumor (MPNST); Neurofibromatosis Type I (NF-1); Melanoma; Schwannomatosis
Intervention: Drug: PLX3397
Sponsors: Plexxikon; Plexxikon
Recruiting - verified May 2012 - Conditions: Breast Cancer; Breast Reconstruction; Cosmesis
Intervention: Procedure: Nipple Sparing Mastectomy
Sponsors: Carolinas Healthcare System; Carolinas Healthcare System
Recruiting - verified June 2011 - Condition: Breast Cancer
Interventions: Other: biologic sample preservation procedure; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Alopecia; Breast Cancer
Interventions: Drug: bimatoprost ophthalmic solution; Drug: placebo
Sponsors: University of California, Los Angeles; University of California, Los Angeles; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: Herceptin / Lapatinib; Drug: Letrozole
Sponsors: Baylor Breast Care Center; Baylor Breast Care Center; Translational Breast Cancer Reserach Consortium; GlaxoSmithKline
Recruiting - verified January 2012 - Condition: Triple Negative Breast Cancer
Intervention: Drug: Temsirolimus, cisplatin, erlotinib
Sponsors: Columbia University; Columbia University; Wyeth is now a wholly owned subsidiary of Pfizer; Genentech
Recruiting - verified October 2011 - Condition: Melanoma
Intervention:
Sponsors: New Mexico Cancer Care Alliance; New Mexico Cancer Care Alliance
Recruiting - verified December 2011 - Condition: Breast Cancer
Intervention: Radiation: Radiation therapy
Sponsors: New York University School of Medicine; New York University School of Medicine; department of radiation oncology
Recruiting - verified November 2011 - Conditions: ErbB2 Overexpressing; Solid Tumors; Metastatic Breast Cancer; Neoplasms, Breast
Intervention: Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified December 2011 - Conditions: Central Nervous System Metastases; Leptomeningeal Metastases; Recurrent Breast Cancer; Stage IV Breast Cancer; Tumors Metastatic to Brain
Interventions: Drug: methotrexate; Drug: liposomal cytarabine; Other: quality-of-life assessment; Other: questionnaire administration
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Breast Cancer
Intervention:
Sponsors: University of Chicago; University of Chicago
Recruiting - verified June 2011 - Conditions: Breast Cancer; Inflammatory Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer
Interventions: Biological: MUC-1 peptide vaccine; Biological: poly ICLC; Biological: MUC1 peptide-poly-ICLC adjuvant vaccine; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Other: flow cytometry
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified March 2012 - Conditions: Atrophic Vaginitis; Breast Cancer
Intervention: Drug: Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012 - Conditions: Breast Cancer; Prostate Cancer; Lung Cancer; Lymphoma Cancer; Gynecological Cancers
Interventions: Behavioral: group intervention and questionnaires; Behavioral: individual phone intervention and questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified December 2011 - Condition: Metastatic Breast Cancer
Interventions: Drug: Cyclosporins; Drug: nab-paclitaxel
Sponsors: Northwestern University; Northwestern University; Avon Foundation
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Broccoli sprout extract (sulforaphane); Dietary Supplement: Mango juice without extract
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; Breast Cancer Research Foundation
Recruiting - verified January 2012 - Condition: Breast Cancer
Intervention: Procedure: PEM Breast Biopsy
Sponsors: University of Cincinnati; University of Cincinnati
Recruiting - verified March 2012 - Condition: Port Wine Stains
Interventions: Drug: Imiquimod (Aldara); Drug: non-medicated petroleum cream
Sponsors: University of Kentucky; University of Kentucky; Graceway Pharmaceuticals, LLC
Recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Dietary Supplement: Coenzyme Q10; Dietary Supplement: Coenzyme Q10 Placebo
Sponsors: Columbia University; Columbia University; National Institutes of Health (NIH)
Recruiting - verified October 2011 - Conditions: Kaposiform Hemangioendotheliomas; Tufted Angioma; Capillary Venous Lymphatic Malformation; Venous Lymphatic Malformation; Microcystic Lymphatic Malformation; Mucocutaneous Lymphangiomatosis and Thrombocytopenia; Capillary Lymphatic Arterial Venous Malformations; PTEN Overgrowth Syndrome With Vascular Anomaly; Lymphangiectasia Syndromes
Intervention: Drug: sirolimus
Sponsors: Children's Hospital Medical Center, Cincinnati; Children's Hospital Medical Center, Cincinnati
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Biological: allogeneic GM-CSF-secreting breast cancer vaccine; Biological: trastuzumab; Drug: cyclophosphamide
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Radiation: Computed Tomography; Radiation: Computed Tomography; Radiation: Computed Tomography
Sponsors: Koning Corporation; Koning Corporation
Recruiting - verified January 2012 - Conditions: Adenocarcinoma; Her2+; Advanced Metastatic Breast Cancer; Metastatic ErbB2; Invasive Breast Cancer; Advanced Breast Cancer; Cancer; ErbB2+
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention: Drug: Capecitabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified May 2012 - Conditions: Lymphedema; Breast Cancer
Interventions: Device: Compression Sleeve; Device: Short-Stretch Compression Bandage
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Metastatic Breast Cancer, Locally Recurrent Breast Cancer
Interventions: Drug: bevacizumab; Drug: GDC-0941; Drug: paclitaxel
Sponsors: Genentech; Genentech
Recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Biological: bevacizumab; Biological: trastuzumab; Drug: carboplatin; Drug: docetaxel; Other: laboratory biomarker analysis
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Breast Cancer
Intervention: Behavioral: Moving Forward Together 2
Sponsors: The Miriam Hospital; The Miriam Hospital; American Cancer Society
Recruiting - verified July 2011 - Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Intervention: Dietary Supplement: Lactobacillus rhamnosus GG
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Conditions: Herpes Simplex Virus; Neonatal Sepsis
Intervention: Drug: Acyclovir
Sponsors: Duke University; Duke University; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified January 2012 - Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Chicago; Dana-Farber Cancer Institute; Georgetown University; Johns Hopkins University; M.D. Anderson Cancer Center; University of Alabama at Birmingham; University of California, San Francisco; University of North Carolina; Duke University; Vanderbilt-Ingram Cancer Center; Indiana University Melvin and Bren Simon Cancer Center; Mayo Clinic; University of Pittsburgh; University of Michigan Health System
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: nab-paclitaxel; Drug: trastuzumab; Drug: Doxorubicin; Drug: cyclophosphamide
Sponsors: University of Kansas; University of Kansas; Celgene Corporation
Recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Drug: Exemestane; Drug: Docetaxel, cytoxan
Sponsors: Emory University; Emory University; Pfizer
Recruiting - verified February 2012 - Condition: Rosacea
Interventions: Drug: DER 45 EV; Drug: Vehicle
Sponsors: Sol-Gel Technologies, Ltd.; Sol-Gel Technologies, Ltd.
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: everolimus; Drug: abraxane
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: docetaxel; Drug: pertuzumab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Psoriasis
Interventions: Drug: Methotrexate; Drug: Adalimumab (Humira)
Sponsors: Tufts Medical Center; Tufts Medical Center; Abbott
Recruiting - verified July 2011 - Conditions: Psoriasis; Nonalcoholic Fatty Liver Disease
Intervention:
Sponsors: George Washington University; George Washington University
Recruiting - verified October 2011 - Conditions: Psoriasis; Metabolic Syndrome
Intervention:
Sponsors: Tufts Medical Center; Tufts Medical Center; Amgen
Recruiting - verified July 2011 - Condition: Breast Cancer
Interventions: Drug: cisplatin; Drug: everolimus; Drug: paclitaxel; Other: placebo
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Breast Cancer
Intervention: Drug: Metformin
Sponsors: Columbia University; Columbia University; Breast Cancer Research Foundation
Recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Behavioral: Experimental 1: exercise with 2 counseling types; Other: Usual Care - written materials
Sponsors: Southern Illinois University; Southern Illinois University; National Cancer Institute (NCI); University of Illinois at Urbana-Champaign
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: Standard Therapy; Procedure: Local Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Device: PEM Flex Solo II PET Scanner
Sponsors: University of Chicago; University of Chicago
Recruiting - verified June 2011 - Condition: Breast Cancer
Intervention: Other: The Survivor Stories Tablet
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified March 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: GDC-0941; Drug: trastuzumab-MCC-DM1; Drug: Trastuzumab
Sponsors: Genentech; Genentech
Recruiting - verified August 2011 - Condition: Diabetic Foot Ulcer
Interventions: Drug: HO/03/03 10µg; Drug: Placebo
Sponsors: HealOr; HealOr; Clinigene International Ltd; Cato Research
Recruiting - verified December 2011 - Conditions: Breast Cancer; Healthy Volunteer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Conditions: Renal Cell Carcinoma; Breast Cancer; Colon Cancer; Lung Cancer; Non-Hodgkin Lymphoma
Intervention: Drug: dimethane sulfonate (DMS612, NSC 281612)
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Conditions: Hepatic Cancer; Pancreatic Ductal Cancer; Colorectal Cancer; Breast Cancer; Gastric Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Metastatic Breast Cancer
Interventions: Drug: Dasatinib; Drug: Ixabepilone
Sponsors: Accelerated Community Oncology Research Network; Accelerated Community Oncology Research Network; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Genetic: fluorescence in situ hybridization; Other: immunohistochemistry staining method; Other: medical chart review; Procedure: fluorescence spectroscopy; Procedure: histopathologic examination; Procedure: light-scattering spectroscopy
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Other: biologic sample preservation procedure; Other: immunohistochemistry staining method; Other: light microscopy; Other: medical chart review; Procedure: histopathologic examination; Procedure: needle biopsy; Procedure: spectroscopy
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Genetic: gene expression analysis; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Drug: Green tea extract supplement; Other: Placebo
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified January 2012 - Condition: Invasive Breast Cancer
Interventions: Drug: Fulvestrant; Drug: Anastrazole
Sponsors: University of Kansas; University of Kansas; AstraZeneca
Recruiting - verified October 2011 - Condition: Diabetic Foot Ulcers
Interventions: Drug: FGF-1 141; Drug: FGF-1 141
Sponsors: Phage Pharmaceuticals, Inc.; Phage Pharmaceuticals, Inc.
Not yet recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Radiation: Radiation Therapy; Drug: Capecitabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Drug: Trastuzumab (Herceptin); Drug: Trastuzumab (Herceptin) plus Everolimus
Sponsors: Emory University; Emory University; Genentech; Novartis Pharmaceuticals
Recruiting - verified November 2011 - Condition: Breast Cancer
Interventions: Radiation: External beam boost; Radiation: whole breast irradiation
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Breast Cancer
Intervention:
Sponsors: University of Connecticut Health Center; University of Connecticut Health Center; National Institute for Biomedical Imaging and Bioengineering (NIBIB); Donaghue Medical Research Foundation
Recruiting - verified June 2011 - Condition: Metastatic Breast Cancer
Intervention: Drug: BZL101
Sponsors: Bionovo; Bionovo
Not yet recruiting - verified February 2012 - Condition: Triple Negative Breast Cancer
Intervention: Drug: NK012
Sponsors: Nippon Kayaku Co.,Ltd.; Nippon Kayaku Co.,Ltd.
Recruiting - verified June 2011 - Condition: Breast Cancer
Intervention: Other: questionaire, blood or saliva sample
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Translational Genomics Research Institute, Phoenix, Arizona.; University of Southern California; University of Virginia; Lund University; Ontario Cancer Registry; Northern California Cancer Center; Fred Hutchinson Cancer Research Center; University of Iowa; Danish Cancer Society; Beckman Research Institute; City of Hope National Medical Center; M.D. Anderson Cancer Center; Vanderbilt University School of Medicine; New York University School of Medicine; University of Chicago; University of California, Irvine; Stanford University
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: molecular genetic technique; Other: immunohistochemistry staining method
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; North Central Cancer Treatment Group; Southwest Oncology Group
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Other: laboratory biomarker analysis; Other: medical chart review
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Non-melanomatous Skin Cancer; Pancreatic Cancer; Small Intestine Cancer; Testicular Germ Cell Tumor
Interventions: Genetic: in situ hybridization; Genetic: protein expression analysis; Other: immunologic technique
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Breast Cancer; Healthy, no Evidence of Disease
Interventions: Procedure: Random fine need aspiration (rFNA); Other: Mammogram
Sponsors: Northwestern University; Northwestern University; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Genetic: comparative genomic hybridization; Genetic: microarray analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: diagnostic laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2008 - Condition: Breast Cancer
Interventions: Genetic: microarray analysis; Genetic: polymerase chain reaction; Genetic: protein expression analysis; Other: diagnostic laboratory biomarker analysis; Other: fluorescent antibody technique; Other: immunohistochemistry staining method; Other: immunologic technique
Sponsors: National Cancer Institute (NCI); Massachusetts General Hospital; National Cancer Institute (NCI)
Recruiting - verified April 2008 - Condition: Breast Cancer
Interventions: Other: questionnaire administration; Procedure: digital mammography; Procedure: positron emission mammography
Sponsors: Boston Medical Center; Boston Medical Center; Department of Defense
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Other: flow cytometry; Other: fluorescence activated cell sorting; Other: immunohistochemistry staining method; Other: immunologic technique; Other: biomarker analysis
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Genetic: microarray analysis; Procedure: breast biopsy
Sponsors: Georgetown University; Georgetown University; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: enalapril maleate
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified May 2012 - Conditions: Breast Cancer; Hypercalcemia of Malignancy; Colon Cancer; Endocrine Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Metastatic Cancer; Multiple Myeloma; Parathyroid Neoplasms; Renal Cancer; Thyroid Cancer; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Non-Small Cell Lung Cancer
Intervention: Drug: denosumab
Sponsors: Amgen; Amgen
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Behavioral: Cognitive Rehabilitation; Behavioral: Neurofeedback Training (randomized)
Sponsors: Stanford University; Stanford University
Recruiting - verified April 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: Panitumumab; Drug: Carboplatin; Drug: Gemcitabine
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Amgen; Eli Lilly and Company
Recruiting - verified October 2011 - Conditions: Breast Cancer; Dermatitis
Interventions: Other: Sulforaphane-containing broccoli sprout extracts (active agent); Device: Vehicle (inactive control)
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified April 2012 - Conditions: Psoriasis; Coronary Artery Disease
Intervention: Procedure: CCTA Scan (Coronary CT Angiogram)
Sponsors: University of Michigan; University of Michigan
Recruiting - verified August 2011 - Conditions: Autoinflammatory Syndromes; Physical Urticaria
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2011 - Conditions: Anaphylaxis; Hypotension; Bronchospasm; Angioedema
Interventions: Drug: Epinephrine; Procedure: Bone Marrow Apsiration; Drug: Omalizumab (Xolair)
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2011 - Condition: Breast Neoplasms
Intervention: Biological: 9 Peptides from Her-2/neu, CEA, & CTA
Sponsors: University of Virginia; University of Virginia; National Institutes of Health (NIH)
Recruiting - verified April 2012 - Conditions: Advanced Solid Tumors; Breast Cancer; Inflammatory Breast Cancer; Castleman's Disease; Multiple Myeloma
Intervention: Drug: CX-4945 oral formulation
Sponsors: Cylene Pharmaceuticals; Cylene Pharmaceuticals
Recruiting - verified June 2011 - Condition: Urticaria
Intervention: Drug: abatacept (Orencia ®)
Sponsors: Johns Hopkins University; Johns Hopkins University; Bristol-Myers Squibb
Recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: Sunitinib; Drug: Paclitaxel; Drug: Carboplatin; Drug: Sunitinib
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Pfizer
Recruiting - verified March 2012 - Conditions: Psoriasis; Atopic Dermatitis
Interventions: Other: Blood pressure; Other: Height; Other: Weight; Other: BMI; Other: Waist Circumference
Sponsors: Northwestern University; Northwestern University
Recruiting - verified September 2011 - Condition: Breast Cancer
Interventions: Drug: Everolimus; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Cervical Cancer; Genital Warts
Intervention:
Sponsors: Duke University; Duke University; Centers for Disease Control and Prevention
Recruiting - verified June 2011 - Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Breast Masses; Breast Cysts
Intervention: Procedure: Breast Ultrasound imaging
Sponsors: University of Michigan; University of Michigan; National Institutes of Health (NIH)
Recruiting - verified May 2012 - Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer: Concordance StudyCondition: Breast Cancer
Intervention:
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center
Recruiting - verified August 2011 - Condition: Herpes Simplex
Intervention: Drug: acyclovir sodium
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Breast Cancer
Interventions: Biological: bevacizumab; Biological: pegfilgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Piebaldism; Idiopathic Anaphylaxis; Allergy; Chronic Urticara; Angioedema
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Condition: Breast Cancer Related Fatigue
Interventions: Behavioral: Exercise; Behavioral: Progressive walking and resistance exercise treatment
Sponsors: University of Rochester; University of Rochester; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Conditions: Systemic Lupus Erythematosus; Systemic Sclerosis
Intervention: Procedure: Nonmyeloablative allogeneic stem cell transplant
Sponsors: Duke University; Duke University
Recruiting - verified February 2012 - Conditions: Polymyalgia Rheumatica; Rheumatoid Arthritis; Rheumatic Disease
Intervention:
Sponsors: Lahey Clinic; Lahey Clinic
Recruiting - verified February 2012 - Conditions: Ovarian Cancer; Breast Cancer
Intervention: Other: screening
Sponsors: New York University School of Medicine; New York University School of Medicine; Lynne Cohen Foundation for Ovarian Cancer Research
Recruiting - verified November 2011 - Condition: Breast Cancer
Interventions: Biological: allogeneic GM-CSF-secreting breast cancer vaccine; Biological: trastuzumab; Drug: cyclophosphamide; Other: flow cytometry; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: biopsy
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Mucocutaneous Lymph Node Syndrome; Kawasaki Disease
Interventions: Drug: Etanercept; Drug: Placebo
Sponsors: Seattle Children's Hospital; Michael Portman; FDA Office of Orphan Products Development; Amgen
Recruiting - verified April 2012 - Conditions: Breast Cancer; Precancerous Condition
Interventions: Dietary Supplement: broccoli sprout extract; Other: placebo
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Psoriasis; Melanoma; Non-melanoma Skin Cancer
Intervention: Drug: etanercept
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Amgen
Recruiting - verified August 2011 - Condition: Human Papillomavirus Infection
Interventions: Behavioral: Compliance; Behavioral: Message sidedness
Sponsors: Indiana University; Indiana University; Merck
Recruiting - verified March 2012 - Condition: Breast Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Breast Cancer
Intervention: Radiation: radiation therapy
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified April 2012 - Conditions: Breast Cancer; Pregnancy
Intervention:
Sponsors: Genentech; Genentech
Recruiting - verified November 2011 - Conditions: Breast Neoplasms; Breast Cancer; Cancer of the Breast
Intervention: Drug: Docetaxel and Cytoxan
Sponsors: Emory University; Emory University; Sanofi-Aventis
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: lapatinib; Drug: capecitabine [Xeloda]
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: Sorafenib and Ixabepilone; Drug: Sorafenib and Ixabepilone
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Bayer; Bristol-Myers Squibb
Recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Drug: trastuzumab; Drug: agatolimod sodium; Other: Correlative Studies
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center; Pfizer
Recruiting - verified November 2011 - Condition: Breast Cancer
Intervention: Other: Blood draw and questionaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; New York Medical College; New York Presbyterian Hospital; Weill Medical College of Cornell University
Recruiting - verified January 2012 - Conditions: Male Breast Cancer; Recurrent Breast Cancer; Skin Metastases; Stage IV Breast Cancer
Interventions: Drug: imiquimod; Drug: Abraxane; Other: laboratory biomarker analysis; Genetic: RNA analysis; Other: immunoenzyme technique
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Metastatic Breast Cancer; Metastases, Brain
Interventions: Drug: capecitabine; Drug: lapatinib; Drug: trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention: Drug: Dasatinib and Paclitaxel
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Psoriasis Vulgaris
Interventions: Procedure: injection of botulinum toxin type A.; Procedure: normal saline
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified July 2011 - Conditions: Smouldering Systemic Mastocytosis; Indolent Systemic Mastocytosis; Cutaneous Mastocytosis With Handicap; Mastocytosis
Interventions: Drug: masitinib (AB1010); Drug: placebo
Sponsors: AB Science; AB Science
Recruiting - verified January 2012 - Conditions: Menkes Disease; Occipital Horn Syndrome; Unexplained Copper Deficiency
Intervention: Drug: Copper Histidine
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified September 2011 - Condition: Triple Negative Breast Cancer
Intervention: Drug: gemcitabine plus carboplatin plus BSI-201
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Breast Cancer Research Foundation
Recruiting - verified December 2011 - Condition: Breast Cancer
Interventions: Drug: exemestane; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Conditions: Albinism; Oculocutaneous Albinism; Foveal Hypoplasia; Hypopigmentation; Nystagmus
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified May 2012 - Conditions: Breast Cancer; Breast Neoplasms; Breast Tumors; Cancer; Locally Recurrent and Metastatic Breast Cancer; Metastases; Metastatic Cancer; Oncology; Solid Tumors; Tumors
Interventions: Drug: AMG 386 15 mg/kg, Capecitabine and Lapatinib; Drug: AMG 386 15mg/kg, Paclitaxel and Trastuzumab; Drug: AMG 386 30 mg/kg, Paclitaxel and Trastuzumab; Drug: AMG 386 30 mg/kg, Capecitabine and Lapatinib; Drug: AMG 386 10 mgkg, Paclitaxel and Trastuzumab; Drug: AMG 386 10 mg/kg, Capecitabine and Lapatinib
Sponsors: Amgen; Amgen
Recruiting - verified March 2012 - Condition: Chronic Plaque Psoriasis
Intervention: Biological: HUMIRA® (adalimumab)
Sponsors: Abbott; Abbott
Recruiting - verified January 2012 - Condition: Head and Neck Cancer
Intervention: Radiation: Photon/Proton Beam Radiation Therapy
Sponsors: University of Florida; University of Florida
Recruiting - verified March 2012 - Condition: HIV Lipodystrophy
Interventions: Drug: Growth hormone; Drug: Growth Hormone Releasing Hormone
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Biological: trastuzumab; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: quality-of-life assessment
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Conditions: Breast Cancer; Metastatic Cancer
Interventions: Drug: capecitabine; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Drug: lapatinib ditosylate; Drug: paclitaxel; Drug: vinorelbine ditartrate; Drug: Trastuzumab
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; Department of Defense; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Solid Tumors; Neoplasms, Breast; Cancer
Interventions: Drug: Lapatinib in combination with an anti-cancer agent; Drug: Lapatinib; Drug: Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012 - Conditions: HER2-positive Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine; Procedure: leukapheresis; Biological: ex vivo-expanded HER2-specific T cells; Drug: cyclophosphamide; Other: laboratory biomarker analysis; Biological: sargramostim; Other: flow cytometry; Other: immunoenzyme technique; Genetic: gene expression analysis; Genetic: polymerase chain reaction
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Biological: allogeneic large multivalent immunogen breast cancer vaccine; Biological: aldesleukin
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention: Device: Near-Infrared Tomographic Optical Breast Imaging
Sponsors: Massachusetts General Hospital; Steven Isakoff, MD, PhD
Recruiting - verified April 2012 - Condition: Leukemia
Intervention: Drug: Midostaurin
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention: Drug: Dasatinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention: Drug: Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim
Sponsors: University of Tennessee Cancer Institute; University of Tennessee Cancer Institute; National Comprehensive Cancer Network; Celgene Corporation; Genentech
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Pancreatic Cancer; Gastrointestinal Neoplasms; Colon Rectal Cancer Adenocarcinoma; Esophageal Cancer; Gall Bladder Cancer; Gastric (Stomach) Cancer; Gastrooesophageal Cancer; Gastrointestinal Stromal Tumor (GIST); Hepatobiliary Neoplasm; Liver Carcinoma; Gallbladder Carcinoma; Bile Duct Carcinoma; Carcinoma of the Large Intestine; Anal Cancer
Intervention: Procedure: Observation
Sponsors: Stanford University; Stanford University
Recruiting - verified June 2011 - Condition: Femoral Neck Fractures
Interventions: Device: Open reduction internal fixation (ORIF) with single sliding hip screw; Device: ORIF with multiple cancellous screws
Sponsors: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Canadian Institutes of Health Research (CIHR); Stichting Nuts Ohra (SNO); Physicians Services Incorporated (PSI) Foundation
Recruiting - verified April 2012 - Condition: Metastatic Breast Cancer
Intervention: Drug: lapatinib
Sponsors: University of Kansas; University of Kansas
Recruiting - verified October 2011 - Conditions: Diabetic Foot; Leg Ulcer; Decubitus Ulcer
Intervention:
Sponsors: Southwest Regional Wound Care Center; Southwest Regional Wound Care Center
Recruiting - verified March 2012 - Condition: Takayasu Arteritis
Intervention:
Sponsors: Boston University; Peter A. Merkel; Office of Rare Diseases (ORD); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Rare Diseases Clinical Research Network
Recruiting - verified February 2012 - Conditions: Advanced or Metastatic Solid Tumors; Advanced or Metastatic Breast Cancer
Interventions: Drug: Azacitidine (Vidaza); Drug: Nab-paclitaxel (Abraxane)
Sponsors: University of South Alabama; University of South Alabama; Celgene Corporation
Recruiting - verified August 2011 - Conditions: Breast Cancer; Lung Cancer; Melanoma; Pancreatic Cancer; Solid Tumors
Intervention: Drug: 1-methyl-D-tryptophan
Sponsors: NewLink Genetics Corporation; NewLink Genetics Corporation
Recruiting - verified December 2011 - Conditions: Diabetes Mellitus; Healthy Volunteers
Intervention:
Sponsors: Beth Israel Deaconess Medical Center; Beth Israel Deaconess Medical Center; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified June 2011 - Condition: Breast Cancer
Intervention:
Sponsors: Duke University; Duke University
Recruiting - verified February 2012 - Conditions: Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation; Biological: bevacizumab; Drug: erlotinib hydrochloride; Other: immunohistochemistry staining method; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Breast Cancer; Breast Abnormalities
Intervention: Procedure: digital mammography
Sponsors: University of Michigan; University of Michigan
Recruiting - verified August 2011 - Condition: Breast Cancer
Interventions: Procedure: cryosurgery; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Breast Cancer; Breast Abnormalities
Intervention: Procedure: Computer aided analysis of breast lesions
Sponsors: University of Michigan; University of Michigan; National Institutes of Health (NIH)
Recruiting - verified August 2011 - Condition: Breast Cancer
Interventions: Drug: PD 0332991; Drug: letrozole; Drug: letrozole
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Skin Diseases, Infectious
Interventions: Drug: Daptomycin; Drug: Vancomycin, Clindamycin or semi-synthetic Penicillins
Sponsors: Cubist Pharmaceuticals; Cubist Pharmaceuticals
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Procedure: assessment of therapy complications
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Acne; Actinic Keratosis; Dysplastic Nevi; Eczema; Psoriasis; Skin Cancer; Rosacea; Leg Ulcers; Foot Ulcers; Atopic Dermatitis
Intervention:
Sponsors: University of California, Davis; University of California, Davis
Recruiting - verified June 2011 - Conditions: Aids-related Malignancies; Lymphoma; Precancerous Condition; Sarcoma
Interventions: Genetic: polymerase chain reaction; Other: cytology specimen collection procedure; Other: histological technique; Procedure: colposcopic biopsy
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Metastatic Breast Cancer
Interventions: Drug: Dasatinib + Letrozole; Drug: Letrozole
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; US Oncology Research
Recruiting - verified February 2012 - Conditions: Focal Dermal Hypoplasia (FDH); Goltz Syndrome; X Linked Disorders
Intervention:
Sponsors: Baylor College of Medicine; Baylor College of Medicine; National Institutes of Health (NIH); National Foundation for Ectodermal Dysplasias; March of Dimes
Recruiting - verified June 2011 - Conditions: Breast Cancer; Hereditary Breast/Ovarian Cancer (brca1, brca2)
Interventions: Other: counseling intervention; Other: educational intervention; Other: survey administration; Behavioral: psychosocial assessment and care; Behavioral: supportive care
Sponsors: Georgetown University; Georgetown University; National Cancer Institute (NCI); National Human Genome Research Institute (NHGRI)
Recruiting - verified October 2011 - Conditions: Resected Breast Cancer; Breast Cancer
Intervention: Other: ultrasound scan
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified April 2012 - Condition: Psoriasis
Interventions: Procedure: Narrow band (310-312 nm) ultraviolet light B phototherapy; Drug: etanercept
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified February 2012 - Condition: Lipodystrophy
Intervention: Drug: metreleptin
Sponsors: Amylin Pharmaceuticals, Inc.; Amylin Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Conditions: Metastatic Melanoma; Cutaneous Melanoma
Interventions: Drug: Interferon alpha; Drug: KW2871; Drug: KW2871; Drug: interferon alpha; Drug: KW2871; Drug: Interferon alpha
Sponsors: Ludwig Institute for Cancer Research; Ludwig Institute for Cancer Research; Life Sciences Pharmaceuticals
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Behavioral: Questionnaire; Procedure: Digital Imaging
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Biological: Gene Modified T Cells; Biological: Gene Modified T Cells and Interleukin 2
Sponsors: Roger Williams Medical Center; Roger Williams Medical Center; Department of Defense
Recruiting - verified January 2012 - Conditions: Breast Cancer; Precancerous Condition
Interventions: Other: medical chart review; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: Excess human biological tissue; Procedure: quality-of-life assessment
Sponsors: University of Nebraska; University of Nebraska; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Conditions: Breast Cancer; Depression; Hot Flashes; Psychosocial Effects of Cancer and Its Treatment
Interventions: Drug: citalopram hydrobromide; Drug: escitalopram oxalate; Drug: gabapentin; Drug: sertraline hydrochloride; Drug: tamoxifen citrate; Drug: venlafaxine; Genetic: molecular genetic technique; Other: high performance liquid chromatography; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: adjuvant therapy
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Leishmaniasis
Intervention: Drug: Sodium Stibogluconate (SSG)
Sponsors: U.S. Army Medical Research and Materiel Command; U.S. Army Medical Research and Materiel Command; Walter Reed Army Medical Center
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: ABI-007l albumin-stabilized nanoparticle formulation
Sponsors: Loyola University; Loyola University; Genentech
Recruiting - verified September 2011 - Condition: Breast Cancer
Intervention:
Sponsors: University of Massachusetts, Worcester; University of Massachusetts, Worcester
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: letrozole; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: biopsy; Procedure: therapeutic conventional surgery
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Abnormalities, Radiation-Induced
Intervention:
Sponsors: State University of New York - Upstate Medical University; State University of New York - Upstate Medical University; Carol M. Baldwin Breast Cancer Research Fund, Inc.
Recruiting - verified July 2011 - Conditions: Localized Breast Cancer; Localized Prostate Cancer; Patients Receiving External Beam Radiotherapy
Interventions: Dietary Supplement: Organic Germanium; Dietary Supplement: Placebo
Sponsors: Arizona Oncology Services; Arizona Oncology Services
Recruiting - verified June 2011 - Condition: Breast Cancer
Interventions: Procedure: Alloderm, Questionnaires; Procedure: Without ALLODERM, Questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Michigan; University of North Carolina, Chapel Hill
Recruiting - verified December 2011 - Condition: Metastatic Breast Cancer
Interventions: Drug: Sorafenib; Drug: Letrozole
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; Cancer Institute of New Jersey
Recruiting - verified June 2011 - Condition: Breast Cancer
Intervention:
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Breast Cancer
Interventions: Procedure: breast biopsy; Procedure: histopathologic examination; Procedure: light-scattering spectroscopy; Procedure: therapeutic conventional surgery
Sponsors: Vanderbilt University; Vanderbilt University; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Systemic Scleroderma; Severe Systemic Sclerosis
Interventions: Drug: fludarabine phosphate; Drug: Mycophenolic Acid; Drug: tacrolimus; Radiation: total-body irradiation; Procedure: bone marrow transplantation; Procedure: reduced intensity allogeneic hematopoietic stem cell transplantation; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis; Other: flow cytometry; Procedure: biopsy; Drug: cyclophosphamide
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Biological: Dendritic Cell/Tumor Fusion Vaccine; Drug: Interleukin-12; Drug: Interleukin-12
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Harvard University; Department of Defense; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Breast Cancer,; Advanced Solid Tumors,; Cowden Syndrome
Intervention: Drug: BEZ235
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified November 2011 - Condition: Breast Cancer
Interventions: Dietary Supplement: standardized freeze-dried table grape powder; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Carboplatin; Drug: nab-paclitaxel; Drug: trastuzumab
Sponsors: Brown University; Debora G. Isdale; Yale University
Recruiting - verified February 2012 - Conditions: Atopic Dermatitis; Eczema; Ichthyosis Vulgaris
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified July 2011 - Conditions: Basal Cell Carcinoma; Melanoma; Squamous Cell Carcinoma; Non-Malignant Skin Disorders
Intervention: Procedure: confocal microscopy in vivo
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH)
Recruiting - verified March 2012 - Condition: Breast Cancer
Intervention: Procedure: MRI
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: Doxil; Drug: Carboplatin; Drug: Bevacizumab
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; Cancer Institute of New Jersey
Recruiting - verified October 2011 - Condition: Breast Cancer
Intervention: Device: combined optical and MR imaging
Sponsors: University of California, Irvine; University of California, Irvine
Recruiting - verified August 2011 - Conditions: Breast Cancer; Breast Surgery; Breast Reconstruction; Breast Reduction; Breast Augmentation
Interventions: Behavioral: questionnaires; Behavioral: questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; McMaster University; University College, London; Dartmouth-Hitchcock Medical Center; University of British Columbia; Johns Hopkins University; University of Pittsburgh
Recruiting - verified January 2012 - Condition: Breast Cancer
Intervention: Radiation: IMRT
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified September 2011 - Condition: Skin Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Memorial University Medical Center
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Other: perform dynamic contrast enhanced (DCE) MRI
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Oregon Health and Science University; DeltaPoint,Inc.
Recruiting - verified December 2011 - Conditions: Breast Cancer; Lobular Carcinoma; Invasive Breast Cancer
Intervention: Other: Tissue specimen
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012 - Conditions: Adrenal Cortical Cancer; Brain Cancer; Breast Cancer; CNS Cancer; Colon Cancer; HEENT Cancer; Hodgkin's Disease; Kaposi's Sarcoma; Liver Cancer; Lung Cancer; Non-Hodgkin's Lymphoma; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Rectal Cancer; Renal Cancer; Sarcoma; Squamous Cell Carcinoma; Thyroid Cancer
Interventions: Device: Proton-decoupled 31P MRS at 1.5T; Device: 1H Spectroscopy at 1.5T and 3T
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Columbia University; University of Pennsylvania; St.George's Hospital (England); Royal Marsden NHS Foundation Trust; University Medical Center Nijmegen; Weill Medical College of Cornell University
Recruiting - verified February 2012 - Conditions: Breast Cancer; Colon Cancer; Prostate Cancer
Intervention: Genetic: PCR/PCR/LDR Strategy
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Columbia University; Weill Medical College of Cornell University
Recruiting - verified November 2011 - Conditions: Breast Cancer; Pancreatic Cancer
Intervention: Other: Genotyping
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified November 2011 - Conditions: Breast Neoplasms; Ovarian Neoplasms; Colonic Neoplasms; Prostatic Neoplasms; Uterine Cervical Neoplasms; Leukemia; Lymphoma, Non-Hodgkin
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: Letrozole; Drug: Placebo
Sponsors: University of Kansas; Carol Fabian, MD; Novartis; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Procedure: Sentinel Node Biopsy
Sponsors: University of Arkansas; University of Arkansas
Recruiting - verified January 2012 - Condition: Breast Cancer
Intervention: Procedure: Percutaneous Removal and Margin Ablation
Sponsors: University of Arkansas; University of Arkansas; Department of Health and Human Services; Ethicon Endo-Surgery; RITA Medical Systems
Recruiting - verified January 2012 - Conditions: Breast Cancer; Ovarian Cancer; Colon Cancer; Benign Disease
Intervention: Other: Tear collection
Sponsors: University of Arkansas; University of Arkansas; Tenenbaum Family Foundation
Recruiting - verified January 2012 - Conditions: Melanoma; Breast Cancer; Head and Neck Squamous Cell Cancer; Liver Cancer; Colorectal Cancer; Pancreatic Adenocarcinoma
Interventions: Biological: Vaccinia virus (vvDD-CDSR); Biological: Vaccinia virus (vvDD-CDSR); Biological: Vaccinia virus (vvDD-CDSR)
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: 3'-Deoxy-3'-18F Fluorothymidine; Drug: 3'-Deoxy-3'-18F Fluorothymidine
Sponsors: American College of Radiology Imaging Network; American College of Radiology Imaging Network; Virginia Commonwealth University
Recruiting - verified April 2012 - Condition: Cancer of the Breast
Intervention: Procedure: Axillary Reverse Mapping
Sponsors: University of Arkansas; University of Arkansas
Recruiting - verified January 2012 - Condition: Atopic Dermatitis
Intervention: Drug: Pimecrolimus
Sponsors: Valeant Pharmaceuticals International, Inc.; Valeant Pharmaceuticals International, Inc.; Clinical Research Computing Unit (University of Pennsylvania)
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: sunitinib; Drug: capecitabine; Radiation: WBRT
Sponsors: Baylor Breast Care Center; Baylor Breast Care Center
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Drug: RAD001; Drug: Fulvestrant
Sponsors: University of Kentucky; University of Kentucky; Novartis
Recruiting - verified December 2011 - Condition: Breast Cancer
Interventions: Drug: Arimidex with Faslodex; Drug: Arimidex without Faslodex
Sponsors: Baylor Breast Care Center; Baylor Breast Care Center; AstraZeneca
Recruiting - verified January 2012 - Conditions: Breast Cancer; Stomach Neoplasms; Salivary Gland Neoplasms; Thyroid Cancer
Intervention:
Sponsors: Stanford University; Stanford University
Recruiting - verified April 2012 - Conditions: Breast Cancer; Bone Metastases
Interventions: Drug: Dasatinib; Drug: Zoledronic Acid
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: lapatinib ditosylate; Other: placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI); Breast Cancer Research Foundation
Recruiting - verified November 2011 - Condition: Breast Cancer
Interventions: Drug: Letrozole; Drug: Letrozole
Sponsors: International Breast Cancer Study Group; International Breast Cancer Study Group
Recruiting - verified March 2012 - Conditions: Breast Cancer; Cognitive Side Effects of Cancer Treatments; Stage I, II and III A Breast Cancer
Interventions: Behavioral: Questionnaires, MRI, Comet assay and Cell senescence; Behavioral: Questionnaires, MRI, Comet assay and Cell senescence; Behavioral: Questionnaires, MRI, Comet assay and Cell senescence
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Weill Medical College of Cornell University; The City College of New York; Brigham and Women's Hospital
Recruiting - verified February 2012 - Condition: Healthy Volunteers Only
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified June 2011 - Conditions: Breast Cancer; Metastatic Cancer
Interventions: Drug: lapatinib ditosylate; Genetic: gene expression analysis; Other: diagnostic laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); University of California, San Francisco; National Cancer Institute (NCI)
Recruiting - verified July 2009 - Condition: Breast Cancer
Intervention:
Sponsors: Beth Israel Deaconess Medical Center; Beth Israel Deaconess Medical Center
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Biological: GP2 peptide + GM-CSF vaccine; Biological: GM-CSF (sargramostim); Biological: AE37 + GM-CSF vaccine; Biological: GM-CSF (sargramostim)
Sponsors: San Antonio Military Medical Center; San Antonio Military Medical Center; Antigen Express, Inc.; Norwell, Inc.
Recruiting - verified March 2012 - Conditions: Inflammatory Breast Cancer; Male Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: sunitinib malate; Drug: paclitaxel; Drug: doxorubicin hydrochloride; Drug: cyclophosphamide; Biological: filgrastim; Procedure: therapeutic conventional surgery; Other: laboratory biomarker analysis; Other: flow cytometry
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Psoriasis; Arthritis, Psoriatic
Interventions: Biological: ustekinumab; Biological: Biological therapies other than infliximab and ustekinumab; Drug: conventional systemic agents; Biological: infliximab
Sponsors: Centocor Ortho Biotech Services, L.L.C.; Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified May 2012 - Conditions: Breast Cancer; Pregnancy
Interventions: Drug: 5-Fluorouracil; Drug: Cyclophosphamide; Drug: Doxorubicin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Conditions: Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous
Intervention: Drug: sodium stibogluconate (Pentostam)
Sponsors: University of California, San Francisco; University of California, San Francisco
Available - verified July 2007 - Condition: Breast Cancer
Interventions: Behavioral: Tibetan Yoga; Behavioral: Stretching Program; Other: No Intervention; Behavioral: Questionnaire; Behavioral: Booster Program
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Breast Cancer
Intervention: Other: physiologic testing
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Breast Cancer
Interventions: Drug: Abraxane; Drug: Bevacizumab; Drug: Carboplatin
Sponsors: Duke University; Duke University; Genentech
Recruiting - verified June 2011 - Condition: Atopic Dermatitis
Intervention:
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified March 2012 - Conditions: Psoriasis; Metabolic Syndrome; Hyperlipidemia; Obesity; Hypertension
Intervention: Drug: Etanercept
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Amgen
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Other: Interview; Procedure: Blood and Tissue Collection
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012 - Condition: Skin Cancer
Intervention: Device: Spectral Diagnosis Probe
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; University of Texas
Recruiting - verified March 2012 - Condition: Breast Cancer
Intervention: Procedure: Delayed-Immediate Breast Reconstruction
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Susan G. Komen Breast Cancer Foundation
Recruiting - verified April 2012 - Condition: Psoriasis
Interventions: Drug: Imiquimod; Drug: Clobetasol (glucosteroid); Device: Excimer laser (UVB light) treatment
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; University Hospital Case Medical Center
Recruiting - verified February 2012 - Conditions: Breast Cancer; Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation; Drug: pemetrexed disodium
Sponsors: University of California, Davis; University of California, Davis; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Hermansky-Pudlak Syndrome (HPS); Pulmonary Fibrosis; Oculocutaneous Albinism; Platelet Storage Pool Deficiency; Metabolic Disease
Interventions: Drug: Losartan; Drug: Zileuton; Drug: N-Acetylcysteine; Drug: Prevastatin; Drug: Erythromycin
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified December 2010 - Conditions: HIV Infections; Lipodystrophy
Intervention: Drug: Metreleptin (Leptin)
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; Amylin Pharmaceuticals, Inc.
Recruiting - verified August 2011 - Conditions: Insulin Resistance; Hypertriglyceridemia; Diabetes; Hepatic Steatosis
Intervention: Other: low-fat diet ( Still recruiting )
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; National Institutes of Health (NIH); Takeda Global Research & Development Center, Inc.; Amylin Pharmaceuticals, Inc.
Recruiting - verified August 2011 - Conditions: Dyskeratosis Congenita; Aplastic Anemia
Interventions: Drug: Campath 1H; Drug: Cyclophosphamide; Drug: Fludarabine; Procedure: Total Body Irradiation; Procedure: Stem Cell Transplantation; Drug: ATG
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Other: physiologic testing; Other: screening questionnaire administration; Procedure: breast imaging study; Procedure: radiomammography; Procedure: study of high risk factors
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Skin Cancer
Intervention: Procedure: Optical Imaging
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: Trastuzumab; Drug: Bevacizumab; Drug: Docetaxel
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center; Genentech; Case Comprehensive Cancer Center; University of Pittsburgh
Recruiting - verified April 2012 - Conditions: Metastatic Breast Cancer; Advanced Breast Cancer; Gastrointestinal Stromal Tumor; Hepatocellular Carcinoma; Metastasizing Breast Cancer (F); Metastatic Castration-Resistant Prostrate Cancer; Metastatic Renal Cell Cancer; Non Small Cell Lung Cancer; Pancreatic Islet Cell Carcinoma
Intervention: Drug: sunitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Breast Neoplasms
Interventions: Drug: Sevoflurane; Drug: Sevoflurane
Sponsors: Outcomes Research Consortium; Outcomes Research Consortium
Recruiting - verified May 2012 - Conditions: Brain and Central Nervous System Tumors; Breast Cancer; Cognitive/Functional Effects; Drug/Agent Toxicity by Tissue/Organ; Psychosocial Effects of Cancer and Its Treatment
Interventions: Biological: trastuzumab; Drug: carboplatin; Drug: methotrexate; Drug: sodium thiosulfate
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012 - Condition: Breast Cancer
Intervention: Biological: MAB HER 2 (HERCEPTIN)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Behavioral: Questionnaire; Behavioral: Interview
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Department of Defense
Recruiting - verified May 2012 - Conditions: Lymphedema; Breast Cancer
Intervention: Device: Flexitouch
Sponsors: Stanford University; Stanford University
Recruiting - verified October 2011 - Condition: Breast Cancer
Intervention: Drug: chemotherapy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified September 2011 - Condition: Breast Cancer
Interventions: Drug: naltrexone hydrochloride; Procedure: Positron-emission tomography (PET) / computed tomography (CT)
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012 - Conditions: Systemic Sclerosis; Scleroderma; Pulmonary Hypertension; Pulmonary Arterial Hypertension
Intervention:
Sponsors: Georgetown University; Georgetown University; Gilead Sciences
Recruiting - verified October 2011 - Conditions: Breast Cancer; Cognitive/Functional Effects; Lung Cancer; Metastatic Cancer; Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: stereotactic radiosurgery
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); American College of Surgeons; Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group
Recruiting - verified July 2011 - Conditions: Breast Cancer; Lymphedema; Perioperative/Postoperative Complications
Interventions: Behavioral: exercise intervention; Other: educational intervention; Procedure: assessment of therapy complications; Procedure: complementary or alternative medicine procedure; Procedure: management of therapy complications; Procedure: quality-of-life assessment; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Psoriasis; Mycosis Fungoides
Intervention:
Sponsors: University of California, Davis; University of California, Davis
Recruiting - verified June 2011 - Condition: Southern Tick-Associated Rash Illness
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012 - Condition: Breast Neoplasms
Interventions: Other: Blood draw; Other: Blood draw
Sponsors: Washington University School of Medicine; Washington University School of Medicine; National Institutes of Health (NIH)
Recruiting - verified September 2011 - Condition: Breast Neoplasms
Intervention: Procedure: Biopsies for tissue and blood collection
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified September 2011 - Condition: Breast Cancer
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: lyso-thermosensitive liposomal doxorubicin; Procedure: hyperthermia treatment
Sponsors: National Cancer Institute (NCI); Duke Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified October 2007 - Condition: Leishmaniasis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2012 - Conditions: Pseudoxanthoma Elasticum; PXE
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Breast Cancer; Neoplasm Metastasis
Interventions: Other: Standard supportive care (packed RBC transfusion); Drug: epoetin alfa + packed RBC transfusion
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012 - Condition: Neoplasms, Breast
Intervention: Drug: lapatinib + capecitabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention:
Sponsors: New Mexico Cancer Care Alliance; New Mexico Cancer Care Alliance
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention: Drug: Zometa® (zoledronic acid)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Polyarteritis Nodosa
Intervention:
Sponsors: Boston University; Boston University; Office of Rare Diseases (ORD); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Rare Diseases Clinical Research Network
Recruiting - verified February 2012 - Condition: Temporal Arteritis
Intervention:
Sponsors: Boston University; Peter A. Merkel; Office of Rare Diseases (ORD); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Rare Diseases Clinical Research Network
Recruiting - verified February 2012 - Condition: Takayasu's Arteritis
Intervention:
Sponsors: Boston University; Boston University; Office of Rare Diseases (ORD); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Rare Diseases Clinical Research Network
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified July 2011 - Condition: Breast Cancer
Interventions: Genetic: mutation analysis; Other: counseling intervention
Sponsors: Georgetown University; Georgetown University; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Scleroderma
Intervention: Biological: Hematopoietic stem cell transplantation
Sponsors: Northwestern University; Richard Burt, MD
Recruiting - verified April 2012 - Conditions: Breast Cancer; Cancer Survivor; Depression; Fatigue; Sexual Dysfunction; Sleep Disorders; Spiritual Concerns
Interventions: Other: study of socioeconomic and demographic variables; Procedure: fatigue assessment and management; Procedure: management of therapy complications; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Indiana University Melvin and Bren Simon Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2007 - Conditions: Hyper-IgM Syndrome; Ectodermal Dysplasia
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Biological: sargramostim; Biological: therapeutic autologous dendritic cells; Biological: trastuzumab; Drug: vinorelbine ditartrate
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Precancerous Condition
Interventions: Biological: therapeutic allogeneic lymphocytes; Drug: busulfan; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation; Radiation: Total Body Irradiation (TBI); Drug: Granulocyte colony-stimulating factor (G-CSF); Drug: Phenytoin; Drug: Methotrexate
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: Taxotere; Drug: Adriamycin/Cytoxan; Drug: docetaxol; Drug: doxorubicin
Sponsors: Baylor Breast Care Center; Baylor Breast Care Center; Baylor College of Medicine
Recruiting - verified November 2011 - Conditions: Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms
Intervention: Behavioral: Yoga
Sponsors: Albert Einstein College of Medicine of Yeshiva University; Albert Einstein College of Medicine of Yeshiva University; National Cancer Institute (NCI); The Jacob and Valeria Langeloth Foundation
Recruiting - verified February 2012 - Conditions: Sickle Cell Disease; Thalassemia; Severe Congenital Neutropenia; Diamond-Blackfan Anemia; Shwachman-Diamond Syndrome
Interventions: Drug: Busulfan, Fludarabine, ATG, TLI; Drug: Busulfan, Cyclophosphamide, ATG, GCSF; Drug: Campath, Fludarabine, Cyclophosphamide; Radiation: Total Body Irradiation; Procedure: Stem cell infusion
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota; National Marrow Donor Program
Recruiting - verified April 2012 - Condition: Breast Neoplasms
Intervention:
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital
Recruiting - verified July 2011 - Conditions: Erythema Migrans Lesions; Erythema Migrans
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: AC regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Duke Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified April 2008 - Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal accelerated partial breast irradiation; Radiation: brachytherapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012 - Condition: Brain Neoplasms
Intervention: Drug: ferumoxytol
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI); National Institutes of Health (NIH)
Recruiting - verified March 2012 - Conditions: Kidney Diseases; Glomerulosclerosis, Focal
Interventions: Procedure: Kidney needle biopsy; Procedure: DEXA Scan; Procedure: X-rays; Drug: Retinoids for Podocyte Disease
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified October 2011 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Myelodysplastic Syndromes; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; High Risk Metastatic Gestational Trophoblastic Tumor; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Childhood Rhabdomyosarcoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage II Ovarian Epithelial Cancer; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Ovarian Epithelial Cancer; Stage III Small Lymphocytic Lymphoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Breast Cancer; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: pentostatin; Biological: therapeutic allogeneic lymphocytes; Drug: mycophenolate mofetil; Drug: cyclosporine
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Drug: paclitaxel; Genetic: microarray analysis; Procedure: biopsy; Procedure: neoadjuvant therapy; Drug: Paclitaxel
Sponsors: Georgetown University; Georgetown University; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Spondylitis, Ankylosing
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified January 2012 - Conditions: Nervous System Malformations; Arthropathy, Neurogenic; Urticaria; Papilledema
Intervention: Drug: Anakinra
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified November 2011 - Conditions: Urticaria; Arthropathy; Lymphadenopathy; Nervous System Anomalies
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified January 2012 - Condition: Ankylosing Spondylitis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified February 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified February 2012 - Conditions: Rheumatic Diseases; Rheumatoid Arthritis; Systemic Lupus Erythematosus; Scleroderma; Dermatomyositis; Myositis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Environmental Health Sciences (NIEHS)
Recruiting - verified November 2011 - Condition: Mastocytosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Condition: Xeroderma Pigmentosum
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Mastocytosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Conditions: Breast Neoplasms; Ovarian Neoplasms
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Healthy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011 - Conditions: Rheumatic Diseases; Healthy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified January 2012 - Conditions: Breast Neoplasms; Healthy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Fanconi's Anemia; Anemia, Diamond Blackfan; Dyskeratosis Congenital; Thrombocytopenia; Neutropenia
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Cancer; HIV Infection; Skin Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Breast Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Recruiting - verified March 2012 - Condition: Lipodystrophy
Intervention: Drug: Metreleptin
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified November 2011 - Condition: Rheumatic Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified October 2011 - Conditions: Atypical Mycobacterium Infections; Cystic Fibrosis; Job's Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Conditions: Dermatomyositis; Polymyositis; Idiopathic Inflammatory Myopathy; Healthy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Environmental Health Sciences (NIEHS)
Recruiting - verified September 2011 - Conditions: Arthritis; Synovitis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified October 2011 - Conditions: Connective Tissue Disease; Skin Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Healthy; Skin Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Acquired Immunodeficiency Syndrome; Neoplasm; Skin Disease; HIV Infections
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Acquired Immunodeficiency Syndrome; Neoplasm; Skin Disease; HIV Infections
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Autoimmune Disease; Dermatomyositis; Inclusion Body Myositis; Myositis; Polymyositis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified August 2011 - Condition: Periodic Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified April 2012 - Conditions: Lupus Nephritis; Systemic Lupus Erythematosus
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified January 2012 - Condition: Immunologic Deficiency Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified October 2011 - Conditions: Filariasis; Helminthiasis; Loiasis; Mansonelliasis; Onchocerciasis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012 - Conditions: Cockayne Syndrome; Skin Neoplasm; Xeroderma Pigmentosum
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified June 2011 - Conditions: Albinism; Intestinal Disease; Kidney Disease; Myocardial Disease; Pulmonary Fibrosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified August 2011 - Conditions: Cushing's Syndrome; Hereditary Neoplastic Syndrome; Lentigo; Neoplasm; Testicular Neoplasm
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified June 2011 - Condition: Mastocytosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2012


